WO2014173880A1

WO2014173880A1 - Novel microbiocides

Info

Publication number: WO2014173880A1
Application number: PCT/EP2014/058107
Authority: WO
Inventors: Daniel Stierli; Peter Renold; Ramya Rajan
Original assignee: Syngenta Participations Ag
Priority date: 2013-04-22
Filing date: 2014-04-22
Publication date: 2014-10-30

Abstract

Compounds of formula (I) are as defined in the claims, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.

Description

Novel Microbiocides

The present invention relates to novel microbiocidally active, in particular fungicidally active, oxaborole amide compounds their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants or plant propagation material, harvested food crops by phytopathogenic microorganisms, preferably fungi and to processes for the preparation of these compounds. Preferably these compounds are used in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi. The incidence of serious microbial infections, particularly fungal infections, either systemic or topical, continues to increase for plants.

Fungicides are compounds, of natural or synthetic origin, which act to protect plants against damage caused by fungi. Current methods of agriculture rely heavily on the use of fungicides. In fact, some crops cannot be grown usefully without the use of fungicides. Using fungicides allows a grower to increase the yield of the crop and consequently, increase the value of the crop. Numerous fungicidal agents have been developed. However, the treatment of fungal infestations continues to be a major problem. Furthermore, fungicide resistance has become a serious problem, rendering these agents ineffective for some agricultural uses. As such, a need exists for the development of new fungicidal compounds with improved antifungal properties. It has been found that oxaborole with a specific substitution pattern are novel and have improved microbiocidal activity.

Fungicidally active oxaboroles are described in W09533754, oxaborole amides are described in WO2007078340, WO201 1019616 and WO2010045503 as antiprotozoal agents.

It has been found that certain novel oxaborol amides with a specific substitution pattern have advantageous microbiocidal activity.

The present invention accordingly relates to substituted oxaborol amides of formula (I)

wherein

R-i is fluorine, chlorine, bromine, cyano, Ci-C₄alkyl or d-C₄haloalkyl; R₂ and R₃ are, independently from each other hydrogen, halogen, Ci-C₆alkyl, C₂-C₆alkenyl, C₃- C₆alkinyl, C₃-C₆cycloalkyl, C₃-C₆alkinyl, phenyl or R₂ and R₃ may form a cyclic ring;

W is oxygen, sulphur, nitrogen, d-C₆alkylamino, -C₁-C₄alkyl-0-N=CH-, -0-N=CH-, -0-N=C-(d- C₄alkyl), Ci-C₆alkylene, C₂-C₆alkenylene, C₃-C₆alkinylene, C₃-C₆cycloalkyl, or a direct bond;

or if then A has no meaning W is selected from fluorine, chlorin, bromine, Ci_₄ alkoxy, C-i_₄ alkylthio; n is 0, 1 or 2;

A is an optionally substituted aryl or a optionally substituted heteroaryl wherein the optional substituents for the optionally substituted aryl and a optionally substituted heteroaryl groups are selected from F, CI, Br, I, -OH, -CN, nitro, an oxo substituent, -Ci_₄alkoxy, -Ci_₄ alkylthio, C₁_₄alkyl, C₂_ ₄alkenyl, C₂.₄alkenyl, C₂.₄alkynyl, -C(0)H, -C(0)(d_₄ alkyl), -C(0)(d_₄ alkoxy), -C(0)NH₂, -

C(0)NH(d_₄ alkyl), -C(0)N(d_₄ alkyl)(d_₄ alkyl), -OC(0)NH(d_₄ alkyl), -OC(0)N(d_₄ alkyl)(d_₄ alkyl),-NHC(0)(d_₄ alkyl),- NHC(0)(d_₄ alkoxy), -N(C^ alkyl )C(0)(d_₄ alkyl), -N(d_₄ alkyl )C(0)(d_₄ alkoxy), -OC(O) (Ci_₄ alkyl), -OC(0)(Ci_₄ alkoxy), -Si(d^ alkyl)₃, -Si(Ci_₄ alkoxy)₃, C₆-ioaryl, C₆-ioaryloxy, d-ioarylthio, C₆-ioheteroaryl, -(Ci_₈ - perhaloalkyl) , arylC₂.₆alkynyl, -C₂.₆alkenyl, heteroarylC₂.₆alkynyl, -C₂.₆alkenyl, C₃.₈cycloalkyl, -NR⁸R⁹ where R⁸ and R⁹ are independently H, -Ci_₄alkyl -C₂.₄alkenyl, -C₂_ ₄alkynyl or combine with the interjacent nitrogen to form a five- or six-membered ring which may comprise one or two or three heteroatoms (one or two N, O or S atoms in addition to the interjacent nitrogen atom), in which case the heterocyclic ring is unsubstituted or the heterocyclic ring is substituted by one or two oxo substituent , C₁_₄alkyl groups, -C₂.₄alkenyl or substituted -C₂.₄alkenyl, - C₂_₄alkynyl or substituted -C₂_₄alkynyl, -C(0)H, -C(0)(d_₄ alkyl), -C(0)(d_₄ alkoxy), -C(0)NH₂, - C(0)NH(d_₄ alkyl), -C(0)N(d_₄ alkyl)(d_₄ alkyl), -OC(0)NH(d_₄ alkyl), -OC(0)N(d_₄ alkyl)(d_₄ alkyl),-NHC(0)(d_₄ alkyl),- NHC(0)(d_₄ alkoxy), -N(C^ alkyl )C(0)(d_₄ alkyl), -N(d_₄ alkyl )C(0)(d_₄ alkoxy), -OC(O) (Ci_₄ alkyl), -OC(0)(Ci_₄ alkoxy), -Si(d^ alkyl)₃, -Si(Ci_₄ alkoxy)₃, d-ioaryl, d-ioaryloxy, d-ioarylthio, C₆-ioheteroaryl, -(C1-8 - perhaloalkyl) , aryld_₄alkynyl, -Ci_₆alkynyl, wherein all the alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, arylthio or heteroaryl groups are either substituted or unsubstituted or two neigboured substituents of A form a -0-d-C₄alkyl-0- ring or a -C₄-C₆alkylene- ring together with the carbon atoms to which they are attached and theses rings are optionally substituted by F, CI, Br, -Ci.₄alkoxy;

and agronomically acceptable salts, stereoisomers, diastereoisomers, enantiomers, tautomers, atriopisomers and N-oxides of those compounds.

The invention covers all agronomically acceptable salts, stereoisomers, diastereoisomers, enantiomers, tautomers, atropisomers and N-oxides of those compounds. The compounds of formula (I) may exist in different geometric or optical isomeric forms or in different tautomeric forms. One or more centres of chirality may be present, in which case compounds of the formula (I) may be present as pure enantiomers, mixtures of enantiomers, pure diastereomers or mixtures of diastereomers. There may be double bonds present in the molecule, such as C=C or C=N bonds, in which case compounds of formula (I) may exist as single isomers or mixtures of isomers. Centres of

tautomerisation may be present. This invention covers all such isomers and tautomers and mixtures thereof in all proportions as well as isotopic forms such as deuterated compounds. Also

atropisomerism may occur as a result of a restricted rotation about a single bond. Suitable salts of the compounds of formula (I) include acid addition salts such as those with an inorganic acid such as hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid, or an organic carboxylic acid such as oxalic, tartaric, lactic, butyric, toluic, hexanoic or phthalic acid, or a sulphonic acid such as methane, benzene or toluene sulphonic acid. Other examples of organic carboxylic acids include haloacids such as trifluoroacetic acid.

N-oxides are oxidised forms of tertiary amines or oxidised forms of nitrogen containing heteroaromatic compounds. They are described in many books for example in "Heterocyclic N-oxides" by Angelo Albini and Silvio Pietra, CRC Press, Boca Raton, Florida, 1991.

In the context of the present specification the term "aryl" refers to a ring system which may be mono-, bi- or tricyclic. Examples of such rings include phenyl, naphthalenyl, anthracenyl, indenyl or phenanthrenyl. A preferred aryl group is phenyl.

The term "heteroaryl" refers to an aromatic ring system containing at least one heteroatom and consisting either of a single ring or of two or more fused rings. Preferably, single rings will contain up to three and bicyclic systems up to four heteroatoms which will preferably be chosen from nitrogen, oxygen and sulfur. Examples of such groups include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, furanyl, thiophenyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl and tetrazolyl. A preferred heteroaryl group is pyridine. Examples of bicyclic groups are benzothiophenyl, benzimidazolyl, benzothiadiazolyl, quinolinyl, cinnolinyl and quinoxalinyl.

The term "heterocyclyl" is defined to include heteroaryl and in addition their unsaturated or partially unsaturated analogues such as 4,5,6,7-tetrahydro-benzothiophenyl, 9H-fluorenyl, 3,4-dihydro- 2H-benzo-1 ,4-dioxepinyl, 2,3-dihydro-benzofuranyl, piperidinyl, 1 ,3-dioxolanyl, 1 ,3-dioxanyl, 4,5- dihydro-isoxazolyl, tetrahydrofuranyl and morpholinyl.

The alkyl groups, the alkenyl groups, the alkynyl groups and the alkoxy groups in the compound of formula (I) are either linerar or branched or they are perhalogenated and forming haloalkyl groups, haloalkenyl groups, haloalkynyl groups or haloalkoxy groups. Halogen signifies preferably F, CI, Br, I, and more preferred halogen signifies F or CI. An oxo substituent is =0, thus a oxygene atom doubly bonded to carbon or another element. The term "oxo substituent" thus embraces aldehydes, carboxylic acids, ketones, sulfonic acids, amides and esters.

The preferred substituents of the substituted alkyl groups, the substituted alkenyl groups, the substituted alkynyl groups, the substituted alkoxy groups, substituted aryl groups and / or the aromatic heterocycle groups in the compound of formula (I) are selected from the following substituents F, CI, Br, I, -OH, -CN, nitro, a oxo substituent, -Ci_₄alkoxy, -Ci_₄ alkylthio, C₁_₄alkyl, C₂-₄alkenyl, C₂-₄alkenyl, C₂-₄alkynyl, -C(0)H, -C(0)(d_₄ alkyl), -C(0)(d_₄ alkoxy), -C(0)NH₂, -C(0)NH(d_₄ alkyl), -C(0)N(d_₄ alkylXd.4 alkyl), -OC(0)NH(d_₄ alkyl), -OC(0)N(d_₄ alkyl)(d_₄ alkyl),-NHC(0)(d_₄ alkyl),- NHC(0)(d_₄ alkoxy), -N(d_₄ alkyl )C(0)(d_₄ alkyl), -N(d_₄ alkyl )C(0)(d_₄ alkoxy), -OC(O) (d_₄ alkyl), -OC(0)(Ci-4 alkoxy), -Si(d-₄ alkyl)₃, -Si(d-₄ alkoxy)₃, C₆-ioaryl, C₆-ioaryloxy, C₆-ioarylthio, C₆. -_loheteroaryl, -(Ci_₈ - perhaloalkyl) , aryld-₆alkynyl, -d ealkenyl, heteroaryld-₆alkynyl, -d ealkenyl, C₃. scycloalkyl , -NR⁸R⁹ where R⁸ and R⁹ are independently H, -Ci_₄alkyl -C₂.₄alkenyl, -C₂.₄alkynyl or combine with the interjacent nitrogen to form a five- or six-membered ring which may comprise one or two or three heteroatoms (one or two N, O or S atoms in addition to the interjacent nitrogen atom), in which case the heterocyclic ring is unsubstituted or the heterocyclic ring is substituted by one or two oxo substituent , d_₄ alkyl groups, -C₂.₄alkenyl or substituted -C₂.₄alkenyl, -C₂.₄alkynyl or substituted - C₂_₄alkynyl, -C(0)H, -C(0)(d-4 alkyl), -C(0)(d-4 alkoxy), -C(0)NH₂, -C(0)NH(d_₄ alkyl), -C(0)N(d_₄ alkylXd.4 alkyl), -OC(0)NH(d-4 alkyl), -OC(0)N(d_₄ alkyl)(d_₄ alkyl),-NHC(0)(d_₄ alkyl),- NHC(0)(d_₄ alkoxy), -N(d_₄ alkyl )C(0)(d_₄ alkyl), -N(d_₄ alkyl )C(0)(d_₄ alkoxy), -OC(O) (d_₄ alkyl), -OC(0)(Ci_₄ alkoxy), -Si(C₁_₄ alkyl)₃, -Si(d_₄ alkoxy)₃, d-ioaryl, d-ioaryloxy, d-ioarylthio, C_6-

-_loheteroaryl, -(Ci_₈ - perhaloalkyl) , arylCi_₄alkynyl, -d.₆alkynyl, wherein all the alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, arylthio or heteroaryl groups are either substituted or unsubstituted, preferably these substituents of the substituted groups bear only one further substituent, more preferably these substituents of the substituted groups are not further substituted.

The more preferred substituents of the substituted alkyl groups, alkenyl groups, the alkynyl groups and the alkoxy are selected from the following substituents -OH, CN, F, CI, d_₄alkoxy, -d_₄alkoxy, -d-4 alkylthio, C₁_₄alkyl, C₂-₄alkenyl, C₂-4alkenyl, C₂-4alkinyl, C₆-ioaryl, -d.₄alkylamino. The alkyl groups are branched or linear. The most preferred alkyl groups are methyl, ethyl, propyl, iso-propyl, n-butyl, t- butyl (1 ,1-dimthylethyl), sec-butyl (1-methylpropyl), iso-butyl (2-methylpropyl), pentyl, iso-pentyl (3- methylbutyl, isoamyl), 1-methylpentyl, 1-ethylpentyl, hexyl, heptyl, or octyl. Preferred alkenyl groups are ethenyl, propenyl (1-propenyl, 2-propenyl), butenyl (1-butenyl, 2-butenyl, 3-butenyl, 2- methylpropen-1-yl, 2-methylpropen-2-yl), pentenyl (pent-1-enyl, pent-2-enyl, pent-3-enyl, 2-methylbut- 1-enyl, 3-methylbut-1-enyl, 2-m ethyl but-2-enyl, 3-m ethyl but-2-enyl, 2-methylbut-3-enyl, 3-m ethyl but-3- enyl, 1 ,2-dimethylprop-2-enyl, 1 ,1-dimethylprop-2-enyl). Preferred alkynyl groups are ethinyl, propinyl (prop-1-inyl or prop-2-inyl (propargyl)), butyl (but-1-ynyl, but-2-ynyl, but-3-ynyl), pentinyl (pent-1-inyl, pent-2-inyl, pent-3-inyl, pent-4-yl, 3-methylbut-1-inyl, 2-methylbut-3-inyl, 1-methylbut-3-inyl). The most preferred alkyl groups and the most preferred alkoxy groups are methyl, ethyl, propyl, t-buyl, methoxy and ethoxy groups. Methyl, ethyl and methoxy groups are very particularly preferred.

Preferably the alkyl groups in the compound of formula (I) and/or the alkoxy groups in the compound of formula (I) bear not more than two further substituents, more preferably the alkyl groups in the compound of formula (I) and/or the alkoxy groups in the compound of formula (I) bear not more than one further substituent, most preferred the alkyl groups in the compound of formula (I) and/or the alkoxy groups in the compound of formula (I) are not further substituted.

The aryl and hetero aryl groups unsubtituted or substituted 5- membered or 6-membered aromatic monocyclic which may contain one or two heteroatoms selected from N or S or unsubtituted or substituted 9-membered aromatic bicyclic ring system which may contain one or two heteroatoms selected from N or S. The aryl groups and heteroaryl groups are preferably unsubtituted or substituted 5- membered or 6- membered aromatic monocyclic ring system which may contain one or two heteroatoms selected from N or S wherein the substituents are selected from the group consisting of halogen, hydroxy, d- C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci-C₄haloalkoxy, d- C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups.

The preferred substituents of the substituted aryl groups and heteroaryl groups in the compound of formula (I) are selected from the group consisting of halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, d- C₄alkoxy, d-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci-C₄haloalkoxy, Ci-C₄alkoximino and d- dalkylendioxy; more preferred substituents of the substituted aryl groups or heteroaryl groups in the compound of formula (I) are selected from the following substituents F, CI, CF₃, CN, -OH, nitro, -d_₄ alkyl, -d_₄ alkoxy, -C(0)(C i_₄ alkoxy), -C(0)H, -C(0)(d-₄ alkyl) wherein the alkyl groups are either substituted or unsubstituted.

The most preferred substituents of the substituted aryl groups in the compound of formula (I) are selected from the following substituents, F, CI,— C₁_₄alkyl, d_₄alkoxy, -CN, -C(0)(C i_₄ alkoxy), - C(0)(d-₄ alkyl) and preferably F, CI are the even more preferred substituents of the substituted aryl groups in the compound of formula (I).

In particularly preferred embodiments for the methods and compounds of the invention, the preferred groups for A, R-i, R₂, R₃, R_a, R_b, R_c, R_d and R_e in any combination thereof, are as set out below.

Preferably R-i is fluorine, chlorine, bromine, cyano, d-C₂alkyl or d-C₂haloalkyl;

More preferably R-i is fluorine, chlorine or cyano;

Preferably R₂ and R₃ are, independently from each other hydrogen, halogen, Ci-C₄alkyl, or C₂- dalkenyl, Preferably W is oxygen, sulphur, nitrogen, d-C₆alkylamino,

d-C₆alkylene, C₂- C₆alkenylene, C₃-C₆cycloalkyl, or a direct bond;

or if then A has no meaning W is selected from fluorine, chlorin, bromine, Ci.₄ alkoxy, C-i_₄ alkylthio; More preferably W is oxygen, sulphur, nitrogen, d-C₆alkylamino,

d- C₆alkylene, C₂-C₆alkenylene, C₃-C₆cycloalkyl, or a direct bond;

Still more preferably A has no meaning W is selected from fluorine, chlorin, bromine, Ci.₄ alkoxy, Ci.₄ alkylthio;

Preferably n is 0 or 1 Preferably A is selected from

*

wherein R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups wherein the phenyl, pyridyl, thiophene, imidazole or pyrrazol groups are optionally substituted by F, CI, Br or two neigboured substituents of A form a -0-Ci-C₄alkyl-0- ring or a - C₄alkylene-ring together with the carbon atoms to which they are attached and theses rings are optionally substituted by F, CI, Br, -Ci_₄alkoxy.

More preferably A is selected from

wherein R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups wherein the phenyl, pyridyl, thiophene, imidazole or pyrrazol groups are optionally substituted by F, CI, Br or two neigboured substituents of A form a -0-Ci-C₄alkyl-0- ring or a - C₄alkylene-ring together with the carbon atoms to which they are attached and theses rings are optionally substituted by F, CI, Br, -Ci_₄alkoxy

Most preferably A is selected from

*

wherein R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups wherein the phenyl, pyridyl, thiophene, imidazole or pyrrazol groups are optionally substituted by F, CI, Br or two neigboured substituents of A form a -0-Ci-C₄alkyl-0- ring or a - C₄alkylene-ring together with the carbon atoms to which they are attached and theses rings are optionally substituted by F, CI, Br, -Ci_₄alkoxy Preferably R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl groups optionally substituted by F, CI, Br or two neigboured substituents of A form a -0-Ci-C₄alkyl-0- ring or a -C₄alkylene-ring together with the carbon atoms to which they are attached and theses rings are optionally substituted by F, CI, Br, -Ci_₄alkoxy

More preferably R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, phenyl optionally substituted by F, CI, Br or two neigboured substituents of A form a -0-Ci-C₄alkyl-0- ring or a -C₄alkylene-ring together with the carbon atoms to which they are attached and theses rings are optionally substituted by F, CI, Br, - Ci-₄alkoxy.

In one embodiment the resent invention provides compounds of formula (I) wherein A is

wherein R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_a, R_b, R_c, R_d and R_e are as set out above.

Preferably R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, d- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl groups More preferably R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, or two neigboured substituents of A form a -0-Ci-C₄alkyl-0- ring or a -C₄alkylene-ring together with the carbon atoms to which they are attached and theses rings are optionally substituted by F, CI, Br, -Ci_₄alkoxy.

In one further embodiment the present invention provides compounds of formula (I) wherein A is

wherein R_a, R_b, and R_c independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_a, R_b, and R_c are as set out above.

Preferably R_a, R_b, and R_c independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, Ci-C₄haloalkoxy, d- C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl groups

wherein R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_b, R_c, R_d and R_e are as set out above.

Preferably R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, d- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl groups

wherein R_a, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_a, R_c, R_d and R_e are as set out above.

Preferably R_a, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, d- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl groups

wherein R_a, R_b, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_a, R_b, R_d and R_e are as set out above.

Preferably R_a, R_b, R_d and R_e independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, d- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl groups

wherein R_a and R_b independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_a and R_b are as set out above.

Preferably R_a and R_b independently are selected from the group consisting of hydrogen halogen, d- C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, Ci-C₄haloalkoxy, d- C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl groups

wherein R_a, R_b, and R_c independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_a, R_b and R_c are as set out above.

Preferably R_a, R_b and R_c independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, Ci-C₄haloalkoxy, d- C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl groups

wherein R_a, R_b and R_c independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_a, R_b and R_c are as set out above. Preferably R_a, R_band R_c independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, Ci-C₄haloalkoxy, C C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl groups

wherein R_a, R_b and R_c independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R3, R_a, R_band R_c are as set out above.

Preferably R_a, R_band R_c independently are selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, Ci-C₄haloalkoxy, d- C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl groups

wherein R_c independently is selected from the group consisting of hydrogen halogen, hydroxy, d- C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci-C₄haloalkoxy, d- C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups and R-i, R₂, R₃ and R_c are as set out above.

Preferably R_c independently is selected from the group consisting of hydrogen halogen, Ci-C₄alkyl, d- C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl, Ci-C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxygroups, or phenyl groups

*

The compounds of the invention may be made by a variety of methods. In all compounds shown in the schemes below A, R-i, R₂, R3, R_a, R_b, R_c, R_d ^nd R_e are as defined above.

may be prepared by reacting a compound of formula II

wherein R-i are as defined under formula I; with a compound of formula III

in which A, W, n, R₂ and R₃ are as defined under formula (I), and R* is halogen, hydroxy or

C-i-6 alkoxy, preferably chloro. Some compounds of formula (III) are known and commercially available. The reactions for the preparation of compounds of formula I are advantageously carried out in aprotic inert organic solvents. Such solvents are hydrocarbons such as benzene, toluene, xylene or cyclohexane, chlorinated hydrocarbons such as dichloromethane, trichloromethane,

tetrachloromethane or chlorobenzene, ethers such as diethyl ether, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, tetrahydrofuran or dioxane, nitriles such as acetonitrile or

propionitrile, amides such as Ν,Ν-dimethylformamide, diethylformamide or N-methylpyrrolidinone. The reaction temperatures are advantageously between -20°C and +120°C. In general, the reactions are slightly exothermic and, as a rule, they can be carried out at ambient temperature. To shorten the reaction time, or else to start the reaction, the mixture may be heated briefly to the boiling point of the reaction mixture. The reaction times can also be shortened by adding a few drops of base as reaction catalyst. Suitable bases are, in particular, tertiary amines such as trimethylamine, triethylamine, quinuclidine, 1 ,4-diazabicyclo[2.2.2]octane, 1 ,5-diazabicyclo[4.3.0]non-5-ene or 1 ,5-diazabicyclo- [5.4.0]undec-7-ene. However, inorganic bases such as hydrides, e.g. sodium hydride or calcium hydride, hydroxides, e.g. sodium hydroxide or potassium hydroxide, carbonates such as sodium carbonate and potassium carbonate, or hydrogen carbonates such as potassium hydrogen carbonate and sodium hydrogen carbonate may also be used as bases. The bases can be used as such or else with catalytic amounts of a phase-transfer catalyst, for example a crown ether, in particular 18-crown- 6, or a tetraalkylammonium salt. When R* is hydroxy, a coupling agent, such as benzotriazol-l-yloxytris(dimethylamino)

phosphoniumhexafluorophosphate, bis-(2-oxo-3-oxazolidinyl)-phosphinic acid chloride (BOP-CI), Ν,Ν'-dicyclohexylcarbodiimide (DCC) or 1 , 1 '-carbonyl-diimidazole (CDI), may be used.

The intermediates of formula II

wherein R-i is defined under formula I, preferably wherein R-i is F (CAS Registry Number: 94331 1-50- 0), Ri is CI (CAS Registry Number: 947165-43-7), are known, and described in the literature, for example in Bioorganic & Medicinal Chemistry Letters, 20(24), 7317-7322; 2010, or Journal of

Molecular Biology, 390(2), 196-207; 2009 or Bioorganic & Medicinal Chemistry Letters, 21 (7), 2048- 2054; 201 1

It has now been found that the compounds of formula (I) according to the invention have, for practical purposes, a very advantageous spectrum of activities for protecting useful plants against diseases that are caused by phytopathogenic microorganisams, such as fungi, bacteria or viruses.

The invention therefore also relates to a method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms, wherein a compound of formula (I) is applied as active ingredient to the plants, to parts thereof or the locus thereof. The compounds of formula (I) according to the invention are distinguished by excellent activity at low rates of application, by being well tolerated by plants and by being environmentally safe. They have very useful curative, preventive and systemic properties and are used for protecting numerous useful plants. The compounds of formula (I) can be used to inhibit or destroy the diseases that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later e.g. from phytopathogenic microorganisms.

It is also possible to use compounds of formula (I) as dressing agents for the treatment of plant propagation material, in particular of seeds (fruit, tubers, grains) and plant cuttings (e.g. rice), for the protection against fungal infections as well as against phytopathogenic fungi occurring in the soil.

Furthermore, the compounds of formula (I) according to the invention may be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage or in hygiene management. The methods according to the instant invention are particularly effective to protect useful plants or plant propagation material thereof against phytopathogenic fungi belonging to the following classes: Ascomycetes (e.g. the genus Cochliobolus, Colletotrichum, Fusarium, Gaeumannomyces, Giberella, Monographella, Microdochium, Penicillium, Phoma, Pyricularia, Magnaporthe, Septoria,

Pseudocercosporella, Tapesia and Thielaviopsis); Basidiomycetes (e.g. the genus Phakopsora, Puccinia, Rhizoctonia, Thanatephorus, Sphacelotheca, Tilletia, Typhula and Ustilago); Fungi imperfecti (also known as Deuteromycetes; e.g. the genus Ascochyta, Diplodia, Erysiphe, Fusarium, Helminthosporium, Phomopsis, Pyrenophora and Verticillium); Oomycetes (e.g. Aphanomyces, Peronospora, Peronosclerospora, Phytophthora, Plasmopara, Pseudoperonospora, Pythium); and Zygomycets (e.g. the genus Rhizopus).

Within the scope of the invention, useful plants to be protected typically comprise the following species of plants: cereal (wheat, barley, rye, oat, rice, maize, sorghum and related species); beet (sugar beet and fodder beet); pomes, drupes and soft fruit (apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries and blackberries); leguminous plants (beans, lentils, peas, soybeans); oil plants (rape, mustard, poppy, olives, sunflowers, coconut, castor oil plants, cocoa beans, groundnuts); cucumber plants (pumpkins, cucumbers, melons); fibre plants (cotton, flax, hemp, jute); citrus fruit (oranges, lemons, grapefruit, mandarins); vegetables (spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, paprika); lauraceae (avocado, cinnamomum, camphor) or plants such as tobacco, nuts, coffee, eggplants, sugar cane, tea, pepper, vines, hops, bananas and natural rubber plants, as well as ornamentals. The term "useful plants" is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyrovyl- shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO

(protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® , Herculex I® and LibertyLink®.

The term "useful plants" is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.

Examples of such plants are: YieldGard® (maize variety that expresses a CrylA(b) toxin); YieldGard Rootworm® (maize variety that expresses a CrylllB(b1 ) toxin); YieldGard Plus® (maize variety that expresses a CrylA(b) and a CrylllB(bl ) toxin); Starlink® (maize variety that expresses a Cry9(c) toxin); Herculex I® (maize variety that expresses a CrylF(a2) toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B ® (cotton variety that expresses a CrylA(c) toxin); Bollgard I® (cotton variety that expresses a CrylA(c) toxin); Bollgard II® (cotton variety that expresses a CrylA(c) and a CryllA(b) toxin); VIPCOT® (cotton variety that expresses a VIP toxin); NewLeaf® (potato variety that expresses a CrylllA toxin); NatureGard® Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt11 corn borer (CB) trait), Agrisure® RW (corn rootworm trait) and Protecta®.

The term "crops" is to be understood as including also crop plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.

Toxins that can be expressed by such transgenic plants include, for example, insecticidal proteins from Bacillus cereus or Bacillus popilliae; or insecticidal proteins from Bacillus thuringiensis, such as δ- endotoxins, e.g. CrylAb, CrylAc, Cryl F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1 , Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonising nematodes, for example Photorhabdus spp. or Xenorhabdus spp., such as Photorhabdus

luminescens, Xenorhabdus nematophilus; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as Streptomycetes toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins;

agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl- transferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA-reductase, ion channel blockers, such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases.

In the context of the present invention there are to be understood by δ-endotoxins, for example CrylAb, CrylAc, Cry1 F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1 , Vip2, Vip3 or Vip3A, expressly also hybrid toxins, truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701 ). Truncated toxins, for example a truncated CrylAb, are known. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of Cry3A055, a cathepsin-G-recognition sequence is inserted into a Cry3A toxin (see WO 03/018810).

Examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0 374 753, WO 93/07278, WO 95/34656, EP-A-0 427 529, EP-A-451 878 and WO 03/052073.

The processes for the preparation of such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. Cryl-type

deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0 367 474, EP-A-0 401 979 and WO 90/13651. The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects, but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera).

Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard® (maize variety that expresses a Cry1 Ab toxin); YieldGard Rootworm® (maize variety that expresses a Cry3Bb1 toxin); YieldGard Plus® (maize variety that expresses a Cry1 Ab and a Cry3Bb1 toxin); Starlink® (maize variety that expresses a Cry9C toxin); Herculex I® (maize variety that expresses a Cry1 Fa2 toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CrylAc toxin); Bollgard I® (cotton variety that expresses a CrylAc toxin); Bollgard II® (cotton variety that expresses a CrylAc and a Cry2Ab toxin); VipCot® (cotton variety that expresses a Vip3A and a Cry1 Ab toxin); NewLeaf® (potato variety that expresses a Cry3A toxin); NatureGard®, Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt1 1 corn borer (CB) trait) and Protecta®.

Further examples of such transgenic crops are: 1. Bt11 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a truncated Cry1 Ab toxin. Bt1 1 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

2. Bt176 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a CrylAb toxin. Bt176 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

3. MIR604 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Maize which has been rendered insect-resistant by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-G- protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03/018810.

4. MON 863 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses a Cry3Bb1 toxin and has resistance to certain Coleoptera insects. 5. IPC 531 Cotton from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150 Brussels, Belgium, registration number C/ES/96/02. 6. 1507 Maize from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1 160 Brussels, Belgium, registration number C/NL/00/10. Genetically modified maize for the expression of the protein Cry1 F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium. 7. NK603 * MON 810 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150

Brussels, Belgium, registration number C/GB/02/M3/03. Consists of conventionally bred hybrid maize varieties by crossing the genetically modified varieties NK603 and MON 810. NK603 * MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from Agrobacterium sp. strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a CrylAb toxin obtained from Bacillus thuringiensis subsp. kurstaki which brings about tolerance to certain

Lepidoptera, include the European corn borer.

The term "locus" of a useful plant as used herein is intended to embrace the place on which the useful plants are growing, where the plant propagation materials of the useful plants are sown or where the plant propagation materials of the useful plants will be placed into the soil. An example for such a locus is a field, on which crop plants are growing.

The term "plant propagation material" is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There may be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants may be protected before transplantation by a total or partial treatment by immersion. Preferably "plant propagation material" is understood to denote seeds.

The compounds of formula (I) can be used in unmodified form or, preferably, together with carriers and adjuvants conventionally employed in the art of formulation.

Therefore the invention also relates to compositions for controlling and protecting against

phytopathogenic microorganisms, comprising a compound of formula (I) and an inert carrier, and to a method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms, wherein a composition, comprising a compound of formula (I) as acitve ingredient and an inert carrier, is applied to the plants, to parts thereof or the locus thereof. To this end compounds of formula (I) and inert carriers are conveniently formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.

Suitable carriers and adjuvants (auxiliaries) can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890.

The compounds of formula (I) or compositions, comprising a compound of formula (I) as acitve ingredient and an inert carrier, can be applied to the locus of the plant or plant to be treated, simultaneously or in succession with further compounds. These further compounds can be e.g.

fertilizers or micronutrient donors or other preparations which influence the growth of plants. They can also be selective herbicides as well as insecticides, fungicides, bactericides, nematicides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation.

A preferred method of applying a compound of formula (I), or a composition, comprising a compound of formula (I) as acitve ingredient and an inert carrier, is foliar application. The frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen.

However, the compounds of formula (I) can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field. The compounds of formula (I) may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.

A formulation, i.e. a composition comprising the compound of formula (I) and, if desired, a solid or liquid adjuvant or, if desired as well, a further, other biocidally active ingredient, is prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface-active compounds (surfactants).

The activity of the compositions according to the invention can be broadened considerably, and adapted to prevailing circumstances, by adding other insecticidally, acaricidally and/or fungicidally active ingredients. The mixtures of the compounds of formula I with other insecticidally, acaricidally and/or fungicidally active ingredients may also have further surprising advantages which can also be described, in a wider sense, as synergistic activity. For example, better tolerance by plants, reduced phytotoxicity, insects can be controlled in their different development stages or better behaviour during their production, for example during grinding or mixing, during their storage or during their use.

Suitable additions to active ingredients here are, for example, representatives of the following classes of active ingredients: organophosphorus compounds, nitrophenol derivatives, thioureas, juvenile hormones, formamidines, benzophenone derivatives, ureas, pyrrole derivatives, carbamates, pyrethroids, chlorinated hydrocarbons, acylureas, pyridylmethyleneamino derivatives, macrolides, neonicotinoids and Bacillus thuringiensis preparations.

The following mixtures of the compounds of formula I with active ingredients are preferred (the abbreviation "TX" means "one compound selected from the group consisting of one specific compound listed in Tables 2 to 2400 or a compound selected from Table 3"): an adjuvant selected from the group of substances consisting of petroleum oils (alternative name) (628) + TX,

an acaricide selected from the group of substances consisting of 1 , 1-bis(4-chlorophenyl)-2- ethoxyethanol (lUPAC name) (910) + TX, 2,4-dichlorophenyl benzenesulfonate (lUPAC/Chemical Abstracts name) (1059) + TX, 2-fluoro-A/-methyl-A/-1-naphthylacetamide (lUPAC name) (1295) + TX, 4-chlorophenyl phenyl sulfone (lUPAC name) (981 ) + TX, abamectin (1 ) + TX, acequinocyl (3) + TX, acetoprole [CCN] + TX, acrinathrin (9) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, alpha- cypermethrin (202) + TX, amidithion (870) + TX, amidoflumet [CCN] + TX, amidothioate (872) + TX, amiton (875) + TX, amiton hydrogen oxalate (875) + TX, amitraz (24) + TX, aramite (881 ) + TX, arsenous oxide (882) + TX, AVI 382 (compound code) + TX, AZ 60541 (compound code) + TX, azinphos-ethyl (44) + TX, azinphos-methyl (45) + TX, azobenzene (lUPAC name) (888) + TX, azocyclotin (46) + TX, azothoate (889) + TX, benomyl (62) + TX, benoxafos (alternative name) [CCNj + TX, benzoximate (71 ) + TX, benzyl benzoate (lUPAC name) [CCN] + TX, bifenazate (74) + TX, bifenthrin (76) + TX, binapacryl (907) + TX, brofenvalerate (alternative name) + TX, bromo- cyclen (918) + TX, bromophos (920) + TX, bromophos-ethyl (921 ) + TX, bromopropylate (94) + TX, buprofezin (99) + TX, butocarboxim (103) + TX, butoxycarboxim (104) + TX, butylpyridaben (alternative name) + TX, calcium polysulfide (lUPAC name) (1 1 1 ) + TX, camphechlor (941 ) + TX, carbanolate (943) + TX, carbaryl (1 15) + TX, carbofuran (1 18) + TX, carbophenothion (947) + TX, CGA 50'439 (development code) (125) + TX, chinomethionat (126) + TX, chlorbenside (959) + TX, chlordimeform (964) + TX, chlordimeform hydrochloride (964) + TX, chlorfenapyr (130) + TX, chlorfenethol (968) + TX, chlorfenson (970) + TX, chlorfensulphide (971 ) + TX, chlorfenvinphos (131 ) + TX, chlorobenzilate (975) + TX, chloromebuform (977) + TX, chloromethiuron (978) + TX, chloropropylate (983) + TX, chlorpyrifos (145) + TX, chlorpyrifos-methyl (146) + TX, chlorthiophos (994) + TX, cinerin I (696) + TX, cinerin II (696) + TX, cinerins (696) + TX, clofentezine (158) + TX, closantel (alternative name) [CCN] + TX, coumaphos (174) + TX, crotamiton (alternative name) [CCN] + TX, crotoxyphos (1010) + TX, cufraneb (1013) + TX, cyanthoate (1020) + TX, cyflumetofen (CAS Reg. No.: 400882-07-7) + TX, cyhalothrin (196) + TX, cyhexatin (199) + TX, cypermethrin (201 ) + TX, DCPM (1032) + TX, DDT (219) + TX, demephion (1037) + TX, demephion-0 (1037) + TX, demephion-S (1037) + TX, demeton (1038) + TX, demeton-methyl (224) + TX, demeton-O (1038) + TX, demeton-O-methyl (224) + TX, demeton-S (1038) + TX, demeton-S-methyl (224) + TX, demeton-S-methylsulphon (1039) + TX, diafenthiuron (226) + TX, dialifos (1042) + TX, diazinon (227) + TX, dichlofluanid (230) + TX, dichlorvos (236) + TX, dicliphos (alternative name) + TX, dicofol (242) + TX, dicrotophos (243) + TX, dienochlor (1071 ) + TX, dimefox (1081 ) + TX, dimethoate (262) + TX, dinactin (alternative name) (653) + TX, dinex (1089) + TX, dinex-diclexine (1089) + TX, dinobuton (269) + TX, dinocap (270) + TX, dinocap-4 [CCN] + TX, dinocap-6 [CCN] + TX, dinocton (1090) + TX, dinopenton (1092) + TX, dinosulfon (1097) + TX, dinoterbon (1098) + TX, dioxathion (1 102) + TX, diphenyl sulfone (lUPAC name) (1 103) + TX, disulfiram (alternative name) [CCN] + TX, disulfoton (278) + TX, DNOC (282) + TX, dofenapyn (1 1 13) + TX, doramectin (alternative name) [CCN] + TX, endosulfan (294) + TX, endothion (1 121 ) + TX, EPN (297) + TX, eprinomectin (alternative name) [CCN] + TX, ethion (309) + TX, ethoate-methyl (1 134) + TX, etoxazole (320) + TX, etrimfos (1 142) + TX, fenazaflor (1 147) + TX, fenazaquin (328) + TX, fenbutatin oxide (330) + TX, fenothiocarb (337) + TX, fenpropathrin (342) + TX, fenpyrad (alternative name) + TX, fenpyroximate (345) + TX, fenson (1 157) + TX, fentrifanil (1 161 ) + TX, fenvalerate (349) + TX, fipronil (354) + TX, fluacrypyrim (360) + TX, fluazuron (1 166) + TX, flubenzimine (1 167) + TX, flucycloxuron (366) + TX, flucythrinate (367) + TX, fluenetil (1 169) + TX, flufenoxuron (370) + TX, flumethrin (372) + TX, fluorbenside (1 174) + TX, fluvalinate (1 184) + TX, FMC 1 137 (development code) (1 185) + TX, formetanate (405) + TX, formetanate hydrochloride (405) + TX, formothion (1 192) + TX, formparanate (1 193) + TX, gamma-HCH (430) + TX, glyodin (1205) + TX, halfenprox (424) + TX, heptenophos (432) + TX, hexadecyl cyclopropanecarboxylate (lUPAC/Chemical Abstracts name) (1216) + TX, hexythiazox (441 ) + TX, iodomethane (lUPAC name) (542) + TX, isocarbophos (alternative name) (473) + TX, isopropyl 0-(methoxyaminothiophosphoryl)salicylate (lUPAC name) (473) + TX, ivermectin

(alternative name) [CCN] + TX, jasmolin I (696) + TX, jasmolin II (696) + TX, jodfenphos (1248) + TX, lindane (430) + TX, lufenuron (490) + TX, malathion (492) + TX, malonoben (1254) + TX, mecarbam (502) + TX, mephosfolan (1261 ) + TX, mesulfen (alternative name) [CCN] + TX, methacrifos (1266) + TX, methamidophos (527) + TX, methidathion (529) + TX, methiocarb (530) + TX, methomyl (531 ) + TX, methyl bromide (537) + TX, metolcarb (550) + TX, mevinphos (556) + TX, mexacarbate (1290) + TX, milbemectin (557) + TX, milbemycin oxime (alternative name) [CCN] + TX, mipafox (1293) + TX, monocrotophos (561 ) + TX, morphothion (1300) + TX, moxidectin (alternative name) [CCN] + TX, naled (567) + TX, NC-184 (compound code) + TX, NC- 512 (compound code) + TX, nifluridide (1309) + TX, nikkomycins (alternative name) [CCN] + TX, nitrilacarb (1313) + TX, nitrilacarb 1 :1 zinc chloride complex (1313) + TX, NNI-0101 (compound code) + TX, NNI-0250 (compound code) + TX, omethoate (594) + TX, oxamyl (602) + TX, oxydeprofos (1324) + TX, oxydisulfoton (1325) + TX, pp'-DDT (219) + TX, parathion (615) + TX, permethrin (626) + TX, petroleum oils (alternative name) (628) + TX, phenkapton (1330) + TX, phenthoate (631 ) + TX, phorate (636) + TX, phosalone (637) + TX, phosfolan (1338) + TX, phosmet (638) + TX, phosphamidon (639) + TX, phoxim (642) + TX, pirimiphos-methyl (652) + TX, polychloroterpenes (traditional name) (1347) + TX, polynactins (alternative name) (653) + TX, proclonol (1350) + TX, profenofos (662) + TX, promacyl (1354) + TX, propargite (671 ) + TX, propetamphos (673) + TX, propoxur (678) + TX, prothidathion (1360) + TX, prothoate (1362) + TX, pyrethrin I (696) + TX, pyrethrin II (696) + TX, pyrethrins (696) + TX, pyridaben (699) + TX, pyridaphenthion (701 ) + TX, pyrimidifen (706) + TX, pyrimitate (1370) + TX, quinalphos (711 ) + TX, quintiofos (1381 ) + TX, R-1492 (development code) (1382) + TX, RA-17 (development code) (1383) + TX, rotenone (722) + TX, schradan (1389) + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, SI-0009 (compound code) + TX, sophamide (1402) + TX, spirodiclofen (738) + TX, spiromesifen (739) + TX, SSI-121 (development code) (1404) + TX, sulfiram (alternative name) [CCN] + TX, sulfluramid (750) + TX, sulfotep (753) + TX, sulphur (754) + TX, SZI-121 (development code) (757) + TX, tau-fluvalinate (398) + TX, tebufenpyrad (763) + TX, TEPP (1417) + TX, terbam (alternative name) + TX, tetrachlorvinphos (777) + TX, tetradifon (786) + TX, tetranactin (alternative name) (653) + TX, tetrasul (1425) + TX, thiafenox (alternative name) + TX, thiocarboxime (1431 ) + TX, thiofanox (800) + TX, thiometon (801 ) + TX, thioquinox (1436) + TX, thuringiensin (alternative name) [CCN] + TX, triamiphos (1441 ) + TX, triarathene (1443) + TX, triazophos (820) + TX, triazu ran (alternative name) + TX, trichlorfon (824) + TX, trifenofos (1455) + TX, trinactin (alternative name) (653) + TX, vamidothion (847) + TX, vaniliprole [CCN] and YI-5302 (compound code) + TX,

an algicide selected from the group of substances consisting of bethoxazin [CCN] + TX, copper dioctanoate (lUPAC name) (170) + TX, copper sulfate (172) + TX, cybutryne [CCN] + TX, dichlone (1052) + TX, dichlorophen (232) + TX, endothal (295) + TX, fentin (347) + TX, hyd rated lime [CCN] + TX, nabam (566) + TX, quinoclamine (714) + TX, quinonamid (1379) + TX, simazine (730) + TX, triphenyltin acetate (lUPAC name) (347) and triphenyltin hydroxide (lUPAC name) (347) + TX,

an anthelmintic selected from the group of substances consisting of abamectin (1 ) + TX, crufomate (1011 ) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291 ) + TX, emamectin benzoate (291 ) + TX, eprinomectin (alternative name) [CCN] + TX, ivermectin (alternative name) [CCN] + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, piperazine [CCN] + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) and thiophanate (1435) + TX,

an avicide selected from the group of substances consisting of chloralose (127) + TX, endrin (1 122) + TX, fenthion (346) + TX, pyridin-4-amine (lUPAC name) (23) and strychnine (745) + TX, a bactericide selected from the group of substances consisting of 1-hydroxy-1/-/-pyridine-2-thione

(lUPAC name) (1222) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (lUPAC name) (748) + TX, 8-hydroxyquinoline sulfate (446) + TX, bronopol (97) + TX, copper dioctanoate (lUPAC name) (170) + TX, copper hydroxide (lUPAC name) (169) + TX, cresol [CCN] + TX, dichlorophen (232) + TX, dipyrithione (1 105) + TX, dodicin (1112) + TX, fenaminosulf (1144) + TX, formaldehyde (404) + TX, hydrargaphen (alternative name) [CCN] + TX, kasugamycin (483) + TX, kasugamycin hydrochloride hydrate (483) + TX, nickel bis(dimethyldithiocarbamate) (lUPAC name) (1308) + TX, nitrapyrin (580) + TX, octhilinone (590) + TX, oxolinic acid (606) + TX, oxytetracycline (611 ) + TX, potassium hydroxyquinoline sulfate (446) + TX, probenazole (658) + TX, streptomycin (744) + TX, streptomycin sesquisulfate (744) + TX, tecloftalam (766) + TX, and thiomersal (alternative name) [CCN] + TX, a biological agent selected from the group of substances consisting of Adoxophyes orana GV

(alternative name) (12) + TX, Agrobacterium radiobacter (alternative name) (13) + TX, Amblyseius spp. (alternative name) (19) + TX, Anagrapha falcifera NPV (alternative name) (28) + TX, Anagrus atomus (alternative name) (29) + TX, Aphelinus abdominalis (alternative name) (33) + TX, Aphidius colemani (alternative name) (34) + TX, Aphidoletes aphidimyza (alternative name) (35) + TX,

Autographa californica NPV (alternative name) (38) + TX, Bacillus firmus (alternative name) (48) + TX, Bacillus sphaericus Neide (scientific name) (49) + TX, Bacillus thuringiensis Berliner (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. aizawai (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. israelensis (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. japonensis (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. kurstaki (scientific name) (51 ) + TX,

Bacillus thuringiensis subsp. tenebrionis (scientific name) (51 ) + TX, Beauveria bassiana (alternative name) (53) + TX, Beauveria brongniartii (alternative name) (54) + TX, Chrysoperla carnea

(alternative name) (151 ) + TX, Cryptolaemus montrouzieri (alternative name) (178) + TX, Cydia pomonella GV (alternative name) (191 ) + TX, Dacnusa sibirica (alternative name) (212) + TX, Diglyphus isaea (alternative name) (254) + TX, Encarsia formosa (scientific name) (293) + TX,

Eretmocerus eremicus (alternative name) (300) + TX, Helicoverpa zea NPV (alternative name) (431 ) + TX, Heterorhabditis bacteriophora and H. megidis (alternative name) (433) + TX, Hippodamia convergens (alternative name) (442) + TX, Leptomastix dactylopii (alternative name) (488) + TX, Macrolophus caliginosus (alternative name) (491 ) + TX, Mamestra brassicae NPV (alternative name) (494) + TX, Metaphycus helvolus (alternative name) (522) + TX, Metarhizium anisopliae var.

acridum (scientific name) (523) + TX, Metarhizium anisopliae var. anisopliae (scientific name) (523) + TX, Neodiprion sertifer NPV and N. lecontei NPV (alternative name) (575) + TX, Orius spp.

(alternative name) (596) + TX, Paecilomyces fumosoroseus (alternative name) (613) + TX,

Phytoseiulus persimilis (alternative name) (644) + TX, Spodoptera exigua multicapsid nuclear polyhedrosis virus (scientific name) (741 ) + TX, Steinernema bibionis (alternative name) (742) + TX, Steinernema carpocapsae (alternative name) (742) + TX, Steinernema feltiae (alternative name) (742) + TX, Steinernema glaseri (alternative name) (742) + TX, Steinernema riobrave (alternative name) (742) + TX, Steinernema riobravis (alternative name) (742) + TX, Steinernema scapterisci (alternative name) (742) + TX, Steinernema spp. (alternative name) (742) + TX, Trichogramma spp. (alternative name) (826) + TX, Typhlodromus occidentalis (alternative name) (844) and Verticillium lecanii (alternative name) (848) + TX,

a soil sterilant selected from the group of substances consisting of iodomethane (lUPAC name) (542) and methyl bromide (537) + TX,

a chemosterilant selected from the group of substances consisting of apholate [CCN] + TX, bisazir (alternative name) [CCN] + TX, busulfan (alternative name) [CCN] + TX, diflubenzuron (250) + TX, dimatif (alternative name) [CCN] + TX, hemel [CCN] + TX, hempa [CCN] + TX, metepa [CCN] + TX, methiotepa [CCN] + TX, methyl apholate [CCN] + TX, morzid [CCN] + TX, penfluron (alternative name) [CCN] + TX, tepa [CCN] + TX, thiohempa (alternative name) [CCN] + TX, thiotepa (alternative name) [CCN] + TX, tretamine (alternative name) [CCN] and uredepa (alternative name) [CCN] + TX, an insect pheromone selected from the group of substances consisting of (E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol (lUPAC name) (222) + TX, (E)-tridec-4-en-1-yl acetate (lUPAC name) (829) + TX, (E)-6-methylhept-2-en-4-ol (lUPAC name) (541 ) + TX, (EZ)-tetradeca-4, 10-dien-1-yl acetate (lUPAC name) (779) + TX, (Z)-dodec-7-en-1-yl acetate (lUPAC name) (285) + TX, (Z)-hexadec-l 1- enal (lUPAC name) (436) + TX, (Z)-hexadec-l 1-en-1-yl acetate (lUPAC name) (437) + TX, (Z)- hexadec-13-en-1 1-yn-1-yl acetate (lUPAC name) (438) + TX, (Z)-icos-13-en-10-one (lUPAC name) (448) + TX, (Z)-tetradec-7-en-1-al (lUPAC name) (782) + TX, (Z)-tetradec-9-en-1-ol (lUPAC name) (783) + TX, (Z)-tetradec-9-en-1-yl acetate (lUPAC name) (784) + TX, (7E,9Z)-dodeca-7,9-dien-1-yl acetate (lUPAC name) (283) + TX, (9Z, 1 1 E)-tetradeca-9, 1 1-dien-1-yl acetate (lUPAC name) (780) + TX, (9Z, 12E)-tetradeca-9, 12-dien-1-yl acetate (lUPAC name) (781 ) + TX, 14-methyloctadec-1-ene (lUPAC name) (545) + TX, 4-methylnonan-5-ol with 4-methylnonan-5-one (lUPAC name) (544) + TX, alpha-multistriatin (alternative name) [CCN] + TX, brevicomin (alternative name) [CCN] + TX, codlelure (alternative name) [CCN] + TX, codlemone (alternative name) (167) + TX, cuelure (alternative name) (179) + TX, disparlure (277) + TX, dodec-8-en-1-yl acetate (lUPAC name) (286) + TX, dodec-9-en-1-yl acetate (lUPAC name) (287) + TX, dodeca-8 + TX, 10-dien-1-yl acetate (lUPAC name) (284) + TX, dominicalure (alternative name) [CCN] + TX, ethyl 4-methyloctanoate (lUPAC name) (317) + TX, eugenol (alternative name) [CCN] + TX, frontalin (alternative name) [CCN] + TX, gossyplure (alternative name) (420) + TX, grandlure (421 ) + TX, grandlure I

(alternative name) (421 ) + TX, grandlure II (alternative name) (421 ) + TX, grandlure III (alternative name) (421 ) + TX, grandlure IV (alternative name) (421 ) + TX, hexalure [CCN] + TX, ipsdienol

(alternative name) [CCN] + TX, ipsenol (alternative name) [CCN] + TX, japonilure (alternative name) (481 ) + TX, lineatin (alternative name) [CCN] + TX, litlure (alternative name) [CCN] + TX, looplure (alternative name) [CCN] + TX, medlure [CCN] + TX, megatomoic acid (alternative name) [CCN] + TX, methyl eugenol (alternative name) (540) + TX, muscalure (563) + TX, octadeca-2, 13-dien-1-yl acetate (lUPAC name) (588) + TX, octadeca-3, 13-dien-1-yl acetate (lUPAC name) (589) + TX, orfralure (alternative name) [CCN] + TX, oryctalure (alternative name) (317) + TX, ostramone (alternative name) [CCN] + TX, siglure [CCN] + TX, sordidin (alternative name) (736) + TX, sulcatol (alternative name) [CCN] + TX, tetradec-1 1-en-1-yl acetate (lUPAC name) (785) + TX, trimedlure (839) + TX, trimedlure A (alternative name) (839) + TX, trimedlure B-, (alternative name) (839) + TX, trimedlure B₂ (alternative name) (839) + TX, trimedlure C (alternative name) (839) and trunc-call (alternative name) [CCN] + TX,

an insect repellent selected from the group of substances consisting of 2-(octylthio)ethanol (lUPAC name) (591 ) + TX, butopyronoxyl (933) + TX, butoxy(polypropylene glycol) (936) + TX, dibutyl adipate (lUPAC name) (1046) + TX, dibutyl phthalate (1047) + TX, dibutyl succinate (lUPAC name) (1048) + TX, diethyltoluamide [CCN] + TX, dimethyl carbate [CCN] + TX, dimethyl phthalate [CCN] + TX, ethyl hexanediol (1 137) + TX, hexamide [CCN] + TX, methoquin-butyl (1276) + TX, methylneodecanamide [CCN] + TX, oxamate [CCN] and picaridin [CCN] + TX,

an insecticide selected from the group of substances consisting of 1-dichloro-1-nitroethane

(lUPAC/Chemical Abstracts name) (1058) + TX, 1 , 1-dichloro-2,2-bis(4-ethylphenyl)ethane (lUPAC name) (1056), + TX, 1 ,2-dichloropropane (lUPAC/Chemical Abstracts name) (1062) + TX, 1 ,2- dichloropropane with 1 ,3-dichloropropene (lUPAC name) (1063) + TX, 1-bromo-2-chloroethane (lUPAC/Chemical Abstracts name) (916) + TX, 2,2,2-trichloro-1-(3,4-dichlorophenyl)ethyl acetate (lUPAC name) (1451 ) + TX, 2,2-dichlorovinyl 2-ethylsulphinylethyl methyl phosphate (lUPAC name) (1066) + TX, 2-(1 ,3-dithiolan-2-yl)phenyl dimethylcarbamate (lUPAC/ Chemical Abstracts name) (1 109) + TX, 2-(2-butoxyethoxy)ethyl thiocyanate (lUPAC/Chemical Abstracts name) (935) + TX, 2- (4,5-dimethyl-1 ,3-dioxolan-2-yl)phenyl methylcarbamate (lUPAC/ Chemical Abstracts name) (1084) + TX, 2-(4-chloro-3,5-xylyloxy)ethanol (lUPAC name) (986) + TX, 2-chlorovinyl diethyl phosphate (lUPAC name) (984) + TX, 2-imidazolidone (lUPAC name) (1225) + TX, 2-isovalerylindan-1 ,3-dione (lUPAC name) (1246) + TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate (lUPAC name) (1284) + TX, 2-thiocyanatoethyl laurate (lUPAC name) (1433) + TX, 3-bromo-1-chloroprop-1-ene (lUPAC name) (917) + TX, 3-methyl-1-phenylpyrazol-5-yl dimethylcarbamate (lUPAC name) (1283) + TX, 4-methyl(prop-2-ynyl)amino-3,5-xylyl methylcarbamate (lUPAC name) (1285) + TX, 5,5-dimethyl- 3-oxocyclohex-1-enyl dimethylcarbamate (lUPAC name) (1085) + TX, abamectin (1 ) + TX, acephate (2) + TX, acetamiprid (4) + TX, acethion (alternative name) [CCN] + TX, acetoprole [CCN] + TX, acrinathrin (9) + TX, acrylonitrile (lUPAC name) (861 ) + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, aldrin (864) + TX, allethrin (17) + TX, allosamidin (alternative name) [CCN] + TX, allyxycarb (866) + TX, alpha-cypermethrin (202) + TX, alpha- ecdysone (alternative name) [CCN] + TX, aluminium phosphide (640) + TX, amidithion (870) + TX, amidothioate (872) + TX, aminocarb (873) + TX, amiton (875) + TX, amiton hydrogen oxalate (875) + TX, amitraz (24) + TX, anabasine (877) + TX, athidathion (883) + TX, AVI 382

(compound code) + TX, AZ 60541 (compound code) + TX, azadirachtin (alternative name) (41 ) + TX, azamethiphos (42) + TX, azinphos-ethyl (44) + TX, azinphos-methyl (45) + TX, azothoate (889) + TX, Bacillus thuringiensis delta endotoxins (alternative name) (52) + TX, barium

hexafluorosilicate (alternative name) [CCN] + TX, barium polysulfide (lUPAC/Chemical Abstracts name) (892) + TX, barthrin [CCN] + TX, Bayer 22/190 (development code) (893) + TX, Bayer 22408 (development code) (894) + TX, bendiocarb (58) + TX, benfuracarb (60) + TX, bensultap (66) + TX, beta-cyfluthrin (194) + TX, beta-cypermethrin (203) + TX, bifenthrin (76) + TX, bioallethrin (78) + TX, bioallethrin S-cyclopentenyl isomer (alternative name) (79) + TX,

bioethanomethrin [CCN] + TX, biopermethrin (908) + TX, bioresmethrin (80) + TX, bis(2- chloroethyl) ether (lUPAC name) (909) + TX, bistrifluron (83) + TX, borax (86) + TX, brofenvalerate (alternative name) + TX, bromfenvinfos (914) + TX, bromocyclen (918) + TX, bromo-DDT

(alternative name) [CCN] + TX, bromophos (920) + TX, bromophos-ethyl (921 ) + TX, bufencarb (924) + TX, buprofezin (99) + TX, butacarb (926) + TX, butathiofos (927) + TX, butocarboxim (103) + TX, butonate (932) + TX, butoxycarboxim (104) + TX, butylpyridaben (alternative name) + TX, cadusafos (109) + TX, calcium arsenate [CCN] + TX, calcium cyanide (444) + TX, calcium polysulfide (lUPAC name) (1 1 1 ) + TX, camphechlor (941 ) + TX, carbanolate (943) + TX, carbaryl (1 15) + TX, carbofuran (1 18) + TX, carbon disulfide (lUPAC/Chemical Abstracts name) (945) + TX, carbon tetrachloride (lUPAC name) (946) + TX, carbophenothion (947) + TX, carbosulfan (1 19) + TX, cartap (123) + TX, cartap hydrochloride (123) + TX, cevadine (alternative name) (725) + TX, chlorbicyclen (960) + TX, chlordane (128) + TX, chlordecone (963) + TX, chlordimeform (964) + TX, chlordimeform hydrochloride (964) + TX, chlorethoxyfos (129) + TX, chlorfenapyr (130) + TX, chlorfenvinphos (131 ) + TX, chlorfluazuron (132) + TX, chlormephos (136) + TX, chloroform [CCN] + TX, chloropicrin (141 ) + TX, chlorphoxim (989) + TX, chlorprazophos (990) + TX, chlorpyrifos (145) + TX, chlorpyrifos-methyl (146) + TX, chlorthiophos (994) + TX, chromafenozide (150) + TX, cinerin I (696) + TX, cinerin II (696) + TX, cinerins (696) + TX, cis-resmethrin (alternative name) + TX, cismethrin (80) + TX, clocythrin (alternative name) + TX, cloethocarb (999) + TX, closantel (alternative name) [CCN] + TX, clothianidin (165) + TX, copper acetoarsenite [CCN] + TX, copper arsenate [CCN] + TX, copper oleate [CCN] + TX, coumaphos (174) + TX, coumithoate (1006) + TX, crotamiton (alternative name) [CCN] + TX, crotoxyphos (1010) + TX, crufomate (101 1 ) + TX, cryolite (alternative name) (177) + TX, CS 708 (development code) (1012) + TX, cyanofenphos (1019) + TX, cyanophos (184) + TX, cyanthoate (1020) + TX, cyclethrin [CCN] + TX,

cycloprothrin (188) + TX, cyfluthrin (193) + TX, cyhalothrin (196) + TX, cypermethrin (201 ) + TX, cyphenothrin (206) + TX, cyromazine (209) + TX, cythioate (alternative name) [CCN] + TX, d- limonene (alternative name) [CCN] + TX, cf-tetramethrin (alternative name) (788) + TX, DAEP (1031 ) + TX, dazomet (216) + TX, DDT (219) + TX, decarbofu ran (1034) + TX, deltamethrin (223) + TX, demephion (1037) + TX, demephion-0 (1037) + TX, demephion-S (1037) + TX, demeton (1038) + TX, demeton-methyl (224) + TX, demeton-0 (1038) + TX, demeton-O-methyl (224) + TX, demeton-S (1038) + TX, demeton-S-methyl (224) + TX, demeton-S-methylsulphon (1039) + TX, diafenthiuron (226) + TX, dialifos (1042) + TX, diamidafos (1044) + TX, diazinon (227) + TX, dicapthon (1050) + TX, dichlofenthion (1051 ) + TX, dichlorvos (236) + TX, dicliphos (alternative name) + TX, dicresyl (alternative name) [CCN] + TX, dicrotophos (243) + TX, dicyclanil (244) + TX, dieldrin (1070) + TX, diethyl 5-methylpyrazol-3-yl phosphate (lUPAC name) (1076) + TX, diflubenzuron (250) + TX, dilor (alternative name) [CCN] + TX, dimefluthrin [CCN] + TX, dimefox (1081 ) + TX, dimetan (1085) + TX, dimethoate (262) + TX, dimethrin (1083) + TX,

dimethylvinphos (265) + TX, dimetilan (1086) + TX, dinex (1089) + TX, dinex-diclexine (1089) + TX, dinoprop (1093) + TX, dinosam (1094) + TX, dinoseb (1095) + TX, dinotefuran (271 ) + TX, diofenolan (1099) + TX, dioxabenzofos (1 100) + TX, dioxacarb (1 101 ) + TX, dioxathion (1 102) + TX, disulfoton (278) + TX, dithicrofos (1 108) + TX, DNOC (282) + TX, doramectin (alternative name) [CCN] + TX, DSP (1 1 15) + TX, ecdysterone (alternative name) [CCN] + TX, El 1642 (development code) (1 1 18) + TX, emamectin (291 ) + TX, emamectin benzoate (291 ) + TX, EMPC (1 120) + TX, empenthrin (292) + TX, endosulfan (294) + TX, endothion (1 121 ) + TX, endrin (1 122) + TX, EPBP (1 123) + TX, EPN (297) + TX, epofenonane (1 124) + TX, eprinomectin

(alternative name) [CCN] + TX, esfenvalerate (302) + TX, etaphos (alternative name) [CCN] + TX, ethiofencarb (308) + TX, ethion (309) + TX, ethiprole (310) + TX, ethoate-m ethyl (1 134) + TX, ethoprophos (312) + TX, ethyl formate (lUPAC name) [CCN] + TX, ethyl-DDD (alternative name) (1056) + TX, ethylene dibromide (316) + TX, ethylene dichloride (chemical name) (1 136) + TX, ethylene oxide [CCN] + TX, etofenprox (319) + TX, etrimfos (1 142) + TX, EXD (1 143) + TX, famphur (323) + TX, fenamiphos (326) + TX, fenazaflor (1 147) + TX, fenchlorphos (1 148) + TX, fenethacarb (1 149) + TX, fenfluthrin (1 150) + TX, fenitrothion (335) + TX, fenobucarb (336) + TX, fenoxacrim (1 153) + TX, fenoxycarb (340) + TX, fenpirithrin (1 155) + TX, fenpropathrin (342) + TX, fenpyrad (alternative name) + TX, fensulfothion (1 158) + TX, fenthion (346) + TX, fenthion-ethyl [CCN] + TX, fenvalerate (349) + TX, fipronil (354) + TX, flonicamid (358) + TX, flubendiamide (CAS. Reg. No.: 272451-65-7) + TX, flucofuron (1 168) + TX, flucycloxuron (366) + TX, flucythrinate (367) + TX, fluenetil (1169) + TX, flufenerim [CCN] + TX, flufenoxuron (370) + TX, flufenprox (1 171 ) + TX, flumethrin (372) + TX, fluvalinate (1184) + TX, FMC 1137 (development code) (1185) + TX, fonofos (1 191 ) + TX, formetanate (405) + TX, formetanate hydrochloride (405) + TX, formothion (1 192) + TX, form paranate (1193) + TX, fosmethilan (1 194) + TX, fospirate (1195) + TX, fosthiazate (408) + TX, fosthietan (1196) + TX, furathiocarb (412) + TX, furethrin (1200) + TX, gamma-cyhalothrin (197) + TX, gamma-HCH (430) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, GY-81 (development code) (423) + TX, halfenprox (424) + TX, halofenozide (425) + TX, HCH (430) + TX, HEOD (1070) + TX, heptachlor (1211 ) + TX, heptenophos (432) + TX, heterophos [CCN] + TX, hexaflumuron (439) + TX, HHDN (864) + TX, hydramethylnon (443) + TX, hydrogen cyanide (444) + TX, hydroprene (445) + TX, hyquincarb (1223) + TX, imidacloprid (458) + TX, imiprothrin (460) + TX, indoxacarb (465) + TX,

iodomethane (lUPAC name) (542) + TX, IPSP (1229) + TX, isazofos (1231 ) + TX, isobenzan (1232) + TX, isocarbophos (alternative name) (473) + TX, isodrin (1235) + TX, isofenphos (1236) + TX, isolane (1237) + TX, isoprocarb (472) + TX, isopropyl 0-(methoxy- aminothiophosphoryl)salicylate (lUPAC name) (473) + TX, isoprothiolane (474) + TX, isothioate (1244) + TX, isoxathion (480) + TX, ivermectin (alternative name) [CCN] + TX, jasmolin I (696) + TX, jasmolin II (696) + TX, jodfenphos (1248) + TX, juvenile hormone I (alternative name) [CCN] + TX, juvenile hormone II (alternative name) [CCN] + TX, juvenile hormone III (alternative name) [CCN] + TX, kelevan (1249) + TX, kinoprene (484) + TX, lambda-cyhalothrin (198) + TX, lead arsenate [CCN] + TX, lepimectin (CCN) + TX, leptophos (1250) + TX, lindane (430) + TX, lirimfos (1251 ) + TX, lufenuron (490) + TX, lythidathion (1253) + TX, m-cumenyl methylcarbamate (lUPAC name) (1014) + TX, magnesium phosphide (lUPAC name) (640) + TX, malathion (492) + TX, malonoben (1254) + TX, mazidox (1255) + TX, mecarbam (502) + TX, mecarphon (1258) + TX, menazon (1260) + TX, mephosfolan (1261 ) + TX, mercurous chloride (513) + TX, mesulfenfos (1263) + TX, metaflumizone (CCN) + TX, metam (519) + TX, metam-potassium (alternative name) (519) + TX, metam-sodium (519) + TX, methacrifos (1266) + TX, methamidophos (527) + TX, methanesulphonyl fluoride (lUPAC/Chemical Abstracts name) (1268) + TX, methidathion (529) + TX, methiocarb (530) + TX, methocrotophos (1273) + TX, methomyl (531 ) + TX, methoprene (532) + TX, methoquin-butyl (1276) + TX, methothrin (alternative name) (533) + TX, methoxychlor (534) + TX, methoxyfenozide (535) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, methylchloroform (alternative name) [CCN] + TX, methylene chloride [CCN] + TX, metofluthrin [CCN] + TX, metolcarb (550) + TX, metoxadiazone (1288) + TX, mevinphos (556) + TX, mexacarbate (1290) + TX, milbemectin (557) + TX, milbemycin oxime (alternative name) [CCN] + TX, mipafox (1293) + TX, mirex (1294) + TX, monocrotophos (561 ) + TX, morphothion (1300) + TX, moxidectin (alternative name) [CCN] + TX, naftalofos (alternative name) [CCN] + TX, naled (567) + TX, naphthalene (lUPAC/Chemical Abstracts name) (1303) + TX, NC-170 (development code) (1306) + TX, NC-184 (compound code) + TX, nicotine (578) + TX, nicotine sulfate (578) + TX, nifluridide (1309) + TX, nitenpyram (579) + TX, nithiazine (1311 ) + TX, nitrilacarb (1313) + TX, nitrilacarb 1 :1 zinc chloride complex (1313) + TX, NNI-0101 (compound code) + TX, NNI-0250 (compound code) + TX, nornicotine (traditional name) (1319) + TX, novaluron (585) + TX, noviflumuron (586) + TX, 0-5-dichloro-4-iodophenyl O-ethyl ethylphosphonothioate (lUPAC name) (1057) + TX, 0,0-diethyl 0-4-methyl-2-oxo-2H-chromen-7-yl phosphorothioate (lUPAC name) (1074) + TX, Ο,Ο-diethyl 0-6-methyl-2-propylpyrimidin-4-yl phosphorothioate (lUPAC name) (1075) + TX, 0,0, 0',Ο'-tetrapropyl dithiopyrophosphate (lUPAC name) (1424) + TX, oleic acid (lUPAC name) (593) + TX, omethoate (594) + TX, oxamyl (602) + TX, oxydemeton-methyl (609) + TX, oxydeprofos (1324) + TX, oxydisulfoton (1325) + TX, pp'-DDT (219) + TX, para-dichlorobenzene [CCN] + TX, parathion (615) + TX, parathion-methyl (616) + TX, penfluron (alternative name) [CCN] + TX, pentachlorophenol (623) + TX, pentachlorophenyl laurate (lUPAC name) (623) + TX, permethrin (626) + TX, petroleum oils (alternative name) (628) + TX, PH 60-38 (development code) (1328) + TX, phenkapton (1330) + TX, phenothrin (630) + TX, phenthoate (631 ) + TX, phorate (636) + TX, phosalone (637) + TX, phosfolan (1338) + TX, phosmet (638) + TX, phosnichlor

(1339) + TX, phosphamidon (639) + TX, phosphine (lUPAC name) (640) + TX, phoxim (642) + TX, phoxim-methyl (1340) + TX, pirimetaphos (1344) + TX, pirimicarb (651 ) + TX, pirimiphos-ethyl

(1345) + TX, pirimiphos-methyl (652) + TX, polychlorodicyclopentadiene isomers (lUPAC name)

(1346) + TX, polychloroterpenes (traditional name) (1347) + TX, potassium arsenite [CCN] + TX, potassium thiocyanate [CCN] + TX, prallethrin (655) + TX, precocene I (alternative name) [CCN] + TX, precocene II (alternative name) [CCN] + TX, precocene III (alternative name) [CCN] + TX, primidophos (1349) + TX, profenofos (662) + TX, profluthrin [CCN] + TX, promacyl (1354) + TX, promecarb (1355) + TX, propaphos (1356) + TX, propetamphos (673) + TX, propoxur (678) + TX, prothidathion (1360) + TX, prothiofos (686) + TX, prothoate (1362) + TX, protrifenbute [CCN] + TX, pymetrozine (688) + TX, pyraclofos (689) + TX, pyrazophos (693) + TX, pyresmethrin (1367) + TX, pyrethrin I (696) + TX, pyrethrin II (696) + TX, pyrethrins (696) + TX, pyridaben (699) + TX, pyridalyl (700) + TX, pyridaphenthion (701 ) + TX, pyrimidifen (706) + TX, pyrimitate (1370) + TX, pyriproxyfen (708) + TX, quassia (alternative name) [CCN] + TX, quinalphos (71 1 ) + TX, quinalphos-methyl (1376) + TX, quinothion (1380) + TX, quintiofos (1381 ) + TX, R-1492

(development code) (1382) + TX, rafoxanide (alternative name) [CCN] + TX, resmethrin (719) + TX, rotenone (722) + TX, RU 15525 (development code) (723) + TX, RU 25475 (development code) (1386) + TX, ryania (alternative name) (1387) + TX, ryanodine (traditional name) (1387) + TX, sabadilla (alternative name) (725) + TX, schradan (1389) + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, SI-0009 (compound code) + TX, SI-0205 (compound code) + TX, SI-0404 (compound code) + TX, SI-0405 (compound code) + TX, silafluofen (728) + TX, SN 72129 (development code) (1397) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoride (lUPAC/Chemical Abstracts name) (1399) + TX, sodium

hexafluorosilicate (1400) + TX, sodium pentachlorophenoxide (623) + TX, sodium selenate (lUPAC name) (1401 ) + TX, sodium thiocyanate [CCN] + TX, sophamide (1402) + TX, spinosad (737) + TX, spiromesifen (739) + TX, spirotetrmat (CCN) + TX, sulcofuron (746) + TX, sulcofuron-sodium (746) + TX, sulfluramid (750) + TX, sulfotep (753) + TX, sulphuryl fluoride (756) + TX, sulprofos (1408) + TX, tar oils (alternative name) (758) + TX, tau-fluvalinate (398) + TX, tazimcarb (1412) + TX, TDE (1414) + TX, tebufenozide (762) + TX, tebufenpyrad (763) + TX, tebupirimfos (764) + TX, teflubenzuron (768) + TX, tefluthrin (769) + TX, temephos (770) + TX, TEPP (1417) + TX, terallethrin (1418) + TX, terbam (alternative name) + TX, terbufos (773) + TX, tetrachloroethane

[CCN] + TX, tetrachlorvinphos (777) + TX, tetramethrin (787) + TX, theta-cypermethrin (204) + TX, thiacloprid (791 ) + TX, thiafenox (alternative name) + TX, thiamethoxam (792) + TX, thicrofos (1428) + TX, thiocarboxime (1431 ) + TX, thiocyclam (798) + TX, thiocyclam hydrogen oxalate (798) + TX, thiodicarb (799) + TX, thiofanox (800) + TX, thiometon (801 ) + TX, thionazin (1434) + TX, thiosultap (803) + TX, thiosultap-sodium (803) + TX, thuringiensin (alternative name) [CCN] + TX, tolfenpyrad (809) + TX, tralomethrin (812) + TX, transfluthrin (813) + TX, transpermethrin (1440) + TX, triamiphos (1441 ) + TX, triazamate (818) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, trichlorfon (824) + TX, trichlormetaphos-3 (alternative name) [CCN] + TX, trichloronat (1452) + TX, trifenofos (1455) + TX, triflumuron (835) + TX, trimethacarb (840) + TX, triprene (1459) + TX, vamidothion (847) + TX, vaniliprole [CCN] + TX, veratridine (alternative name) (725) + TX, veratrine (alternative name) (725) + TX, XMC (853) + TX, xylylcarb (854) + TX, YI-5302 (compound code) + TX, zeta-cypermethrin (205) + TX, zetamethrin (alternative name) + TX, zinc phosphide (640) + TX, zolaprofos (1469) and ZXI 8901 (development code) (858) + TX, cyantraniliprole [736994-63-19] + TX, chlorantraniliprole [500008-45-7] + TX, cyenopyrafen [560121- 52-0] + TX, cyflumetofen [400882-07-7] + TX, pyrifluquinazon [337458-27-2] + TX, spinetoram

[187166-40-1 + 187166-15-0] + TX, spirotetramat [203313-25-1] + TX, sulfoxaflor [946578-00-3] + TX, flufiprole [704886-18-0] + TX, meperfluthrin [915288-13-0] + TX, tetramethylfluthrin [84937-88-2] + TX, a molluscicide selected from the group of substances consisting of bis(tributyltin) oxide (lUPAC name) (913) + TX, bromoacetamide [CCN] + TX, calcium arsenate [CCN] + TX, cloethocarb (999) + TX, copper acetoarsenite [CCN] + TX, copper sulfate (172) + TX, fentin (347) + TX, ferric phosphate (lUPAC name) (352) + TX, metaldehyde (518) + TX, methiocarb (530) + TX, niclosamide (576) + TX, niclosamide-olamine (576) + TX, pentachlorophenol (623) + TX, sodium

pentachlorophenoxide (623) + TX, tazimcarb (1412) + TX, thiodicarb (799) + TX, tributyltin oxide (913) + TX, trifenmorph (1454) + TX, trimethacarb (840) + TX, triphenyltin acetate (lUPAC name) (347) and triphenyltin hydroxide (lUPAC name) (347) + TX, pyriprole [394730-71-3] + TX,

a nematicide selected from the group of substances consisting of AKD-3088 (compound code) + TX, 1 ,2-dibromo-3-chloropropane (lUPAC/Chemical Abstracts name) (1045) + TX, 1 ,2-dichloropropane (lUPAC/ Chemical Abstracts name) (1062) + TX, 1 ,2-dichloropropane with 1 ,3-dichloropropene (lUPAC name) (1063) + TX, 1 ,3-dichloropropene (233) + TX, 3,4-dichlorotetrahydrothiophene 1 ,1- dioxide (lUPAC/Chemical Abstracts name) (1065) + TX, 3-(4-chlorophenyl)-5-methylrhodanine (lUPAC name) (980) + TX, 5-methyl-6-thioxo-1 ,3,5-thiadiazinan-3-ylacetic acid (lUPAC name) (1286) + TX, 6-isopentenylaminopurine (alternative name) (210) + TX, abamectin (1 ) + TX, acetoprole [CCN] + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, AZ 60541

(compound code) + TX, benclothiaz [CCN] + TX, benomyl (62) + TX, butylpyridaben (alternative name) + TX, cadusafos (109) + TX, carbofuran (1 18) + TX, carbon disulfide (945) + TX, carbosulfan (1 19) + TX, chloropicrin (141 ) + TX, chlorpyrifos (145) + TX, cloethocarb (999) + TX, cytokinins (alternative name) (210) + TX, dazomet (216) + TX, DBCP (1045) + TX, DCIP (218) + TX, diamidafos (1044) + TX, dichlofenthion (1051 ) + TX, dicliphos (alternative name) + TX, dimethoate (262) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291 ) + TX, emamectin benzoate (291 ) + TX, eprinomectin (alternative name) [CCN] + TX, ethoprophos (312) + TX, ethylene dibromide (316) + TX, fenamiphos (326) + TX, fenpyrad (alternative name) + TX, fensulfothion (1 158) + TX, fosthiazate (408) + TX, fosthietan (1 196) + TX, furfural (alternative name) [CCN] + TX, GY-81 (development code) (423) + TX, heterophos [CCN] + TX, iodomethane (lUPAC name) (542) + TX, isamidofos (1230) + TX, isazofos (1231 ) + TX, ivermectin (alternative name) [CCN] + TX, kinetin (alternative name) (210) + TX, mecarphon (1258) + TX, metam (519) + TX, metam-potassium (alternative name) (519) + TX, metam-sodium (519) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, Myrothecium verrucaria composition (alternative name) (565) + TX, NC-184 (compound code) + TX, oxamyl (602) + TX, phorate (636) + TX,

phosphamidon (639) + TX, phosphocarb [CCN] + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) + TX, terbam (alternative name) + TX, terbufos (773) + TX, tetrachlorothiophene (lUPAC/ Chemical Abstracts name) (1422) + TX, thiafenox

(alternative name) + TX, thionazin (1434) + TX, triazophos (820) + TX, triazu ran (alternative name) + TX, xylenols [CCN] + TX, YI-5302 (compound code) and zeatin (alternative name) (210) + TX, fluensulfone [318290-98-1] + TX,

a nitrification inhibitor selected from the group of substances consisting of potassium ethylxanthate [CCN] and nitrapyrin (580) + TX,

a plant activator selected from the group of substances consisting of acibenzolar (6) + TX, acibenzolar-S-methyl (6) + TX, probenazole (658) and Reynoutria sachalinensis extract (alternative name) (720) + TX,

a rodenticide selected from the group of substances consisting of 2-isovalerylindan-1 ,3-dione (lUPAC name) (1246) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (lUPAC name) (748) + TX, alpha- chlorohydrin [CCN] + TX, aluminium phosphide (640) + TX, antu (880) + TX, arsenous oxide (882) + TX, barium carbonate (891 ) + TX, bisthiosemi (912) + TX, brodifacoum (89) + TX,

bromadiolone (91 ) + TX, bromethalin (92) + TX, calcium cyanide (444) + TX, chloralose (127) + TX, chlorophacinone (140) + TX, cholecalciferol (alternative name) (850) + TX, coumachlor (1004) + TX, coumafuryl (1005) + TX, coumatetralyl (175) + TX, crimidine (1009) + TX, difenacoum (246) + TX, difethialone (249) + TX, diphacinone (273) + TX, ergocalciferol (301 ) + TX, flocoumafen (357) + TX, fluoroacetamide (379) + TX, flupropadine (1 183) + TX, flupropadine hydrochloride (1 183) + TX, gamma-HCH (430) + TX, HCH (430) + TX, hydrogen cyanide (444) + TX, iodomethane (lUPAC name) (542) + TX, lindane (430) + TX, magnesium phosphide (lUPAC name) (640) + TX, methyl bromide (537) + TX, norbormide (1318) + TX, phosacetim (1336) + TX, phosphine (lUPAC name) (640) + TX, phosphorus [CCN] + TX, pindone (1341 ) + TX, potassium arsenite [CCN] + TX, pyrinuron (1371 ) + TX, scilliroside (1390) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoroacetate (735) + TX, strychnine (745) + TX, thallium sulfate [CCN] + TX, warfarin (851 ) and zinc phosphide (640) + TX,

a synergist selected from the group of substances consisting of 2-(2-butoxyethoxy)ethyl piperonylate (lUPAC name) (934) + TX, 5-(1 ,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone (lUPAC name) (903) + TX, farnesol with nerolidol (alternative name) (324) + TX, MB-599 (development code) (498) + TX, MGK 264 (development code) (296) + TX, piperonyl butoxide (649) + TX, piprotal (1343) + TX, propyl isomer (1358) + TX, S421 (development code) (724) + TX, sesamex (1393) + TX, sesasmolin (1394) and sulfoxide (1406) + TX, an animal repellent selected from the group of substances consisting of anthraquinone (32) + TX, chloralose (127) + TX, copper naphthenate [CCN] + TX, copper oxychloride (171 ) + TX, diazinon (227) + TX, dicyclopentadiene (chemical name) (1069) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, methiocarb (530) + TX, pyridin-4-amine (lUPAC name) (23) + TX, thiram (804) + TX, trimethacarb (840) + TX, zinc naphthenate [CCN] and ziram (856) + TX,

a virucide selected from the group of substances consisting of imanin (alternative name) [CCN] and ribavirin (alternative name) [CCN] + TX,

a wound protectant selected from the group of substances consisting of mercuric oxide (512) + TX, octhilinone (590) and thiophanate-methyl (802) + TX,

and biologically active compounds selected from the group consisting of azaconazole (60207-31-0] + TX, bitertanol [70585-36-3] + TX, bromuconazole [1 16255-48-2] + TX, cyproconazole [94361-06-5] + TX, difenoconazole [1 19446-68-3] + TX, diniconazole [83657-24-3] + TX, epoxiconazole

[106325-08-0] + TX, fenbuconazole [1 14369-43-6] + TX, fluquinconazole [136426-54-5] + TX, flusilazole [85509-19-9] + TX, flutriafol [76674-21-0] + TX, hexaconazole [79983-71-4] + TX, imazalil [35554-44-0] + TX, imibenconazole [86598-92-7] + TX, ipconazole [125225-28-7] + TX, metconazole [1251 16-23-6] + TX, myclobutanil [88671-89-0] + TX, pefurazoate [101903-30-4] + TX, penconazole [66246-88-6] + TX, prothioconazole [178928-70-6] + TX, pyrifenox [88283-41-4] + TX, prochloraz [67747-09-5] + TX, propiconazole [60207-90-1] + TX, simeconazole [149508-90-7] + TX, tebuconazole [107534-96-3] + TX, tetraconazole [1 12281-77-3] + TX, triadimefon [43121-43-3] + TX, triad imenol [55219-65-3] + TX, triflumizole [99387-89-0] + TX, triticonazole [131983-72-7] + TX, ancymidol [12771-68-5] + TX, fenarimol [60168-88-9] + TX, nuarimol [63284-71-9] + TX, bupirimate [41483-43-6] + TX, dimethirimol [5221-53-4] + TX, ethirimol [23947-60-6] + TX, dodemorph [1593-77-7] + TX, fenpropidine [67306-00-7] + TX, fenpropimorph [67564-91-4] + TX, spiroxamine [1 18134-30-8] + TX, tridemorph [81412-43-3] + TX, cyprodinil [121552-61-2] + TX, mepanipyrim [1 10235-47-7] + TX, pyrimethanil [531 12-28-0] + TX, fenpiclonil [74738-17-3] + TX, fludioxonil [131341-86-1] + TX, benalaxyl [71626-1 1-4] + TX, furalaxyl [57646-30-7] + TX, meta- laxyl [57837-19-1] + TX, R-metalaxyl [70630-17-0] + TX, ofurace [58810-48-3] + TX, oxadixyl [77732-09-3] + TX, benomyl [17804-35-2] + TX, carbendazim [10605-21-7] + TX, debacarb

[62732-91-6] + TX, fuberidazole [3878-19-1] + TX, thiabendazole [148-79-8] + TX, chlozolinate [84332-86-5] + TX, dichlozoline [24201-58-9] + TX, iprodione [36734-19-7] + TX, myclozoline [54864-61-8] + TX, procymidone [32809-16-8] + TX, vinclozoline [50471-44-8] + TX, boscalid [188425-85-6] + TX, carboxin [5234-68-4] + TX, fenfuram [24691-80-3] + TX, flutolanil [66332-96- 5] + TX, mepronil [55814-41-0] + TX, oxycarboxin [5259-88-1] + TX, penthiopyrad [183675-82-3] + TX, thifluzamide [130000-40-7] + TX, guazatine [108173-90-6] + TX, dodine [2439-10-3] [1 12-65- 2] (free base) + TX, iminoctadine [13516-27-3] + TX, azoxystrobin [131860-33-8] + TX, dimoxystrobin [149961-52-4] + TX, enestroburin {Proc. BCPC, Int. Congr., Glasgow, 2003, 1 , 93} + TX, fluoxastrobin [361377-29-9] + TX, kresoxim-methyl [143390-89-0] + TX, metominostrobin [133408-50-1] + TX, trifloxystrobin [141517-21-7] + TX, orysastrobin [248593-16-0] + TX, picoxystrobin [1 17428-22-5] + TX, pyraclostrobin [175013-18-0] + TX, ferbam [14484-64-1] + TX, mancozeb [8018-01-7] + TX, maneb [12427-38-2] + TX, metiram [9006-42-2] + TX, propineb [12071-83-9] + TX, thiram [137-26-8] + TX, zineb [12122-67-7] + TX, ziram [137-30-4] + TX, captafol [2425-06-1] + TX, captan [133-06-2] + TX, dichlofluanid [1085-98-9] + TX, fluoroimide [41205-21-4] + TX, folpet [133-07-3 ] + TX, tolylfluanid [731-27-1] + TX, bordeaux mixture [8011- 63-0] + TX, copperhydroxid [20427-59-2] + TX, copperoxychlorid [1332-40-7] + TX, coppersulfat [7758-98-7] + TX, copperoxid [1317-39-1] + TX, mancopper [53988-93-5] + TX, oxine-copper [10380-28-6] + TX, dinocap [131-72-6] + TX, nitrothal-isopropyl [10552-74-6] + TX, edifenphos [17109-49-8] + TX, iprobenphos [26087-47-8] + TX, isoprothiolane [50512-35-1] + TX, phosdiphen [36519-00-3] + TX, pyrazophos [13457-18-6] + TX, tolclofos-methyl [57018-04-9] + TX, acibenzo- lar-S-methyl [135158-54-2] + TX, anilazine [101-05-3] + TX, benthiavalicarb [413615-35-7] + TX, blasticidin-S [2079-00-7] + TX, chinomethionat [2439-01-2] + TX, chloroneb [2675-77-6] + TX, chlorothalonil [1897-45-6] + TX, cyflufenamid [180409-60-3] + TX, cymoxanil [57966-95-7] + TX, dichlone [117-80-6] + TX, diclocymet [139920-32-4] + TX, diclomezine [62865-36-5] + TX, dicloran [99-30-9] + TX, diethofencarb [87130-20-9] + TX, dimethomorph [110488-70-5] + TX, SYP-LI90 (Flumorph) [211867-47-9] + TX, dithianon [3347-22-6] + TX, ethaboxam [162650-77-3] + TX, etridiazole [2593-15-9] + TX, famoxadone [131807-57-3] + TX, fenamidone [161326-34-7] + TX, fenoxanil [115852-48-7] + TX, fentin [668-34-8] + TX, ferimzone [89269-64-7] + TX, fluazinam

[79622-59-6] + TX, fluopicolide [239110-15-7] + TX, flusulfamide [106917-52-6] + TX, fenhexamid [126833-17-8] + TX, fosetyl-aluminium [39148-24-8] + TX, hymexazol [10004-44-1] + TX, iprovalicarb [140923-17-7] + TX, IKF-916 (Cyazofamid) [120116-88-3] + TX, kasugamycin [6980- 18-3] + TX, methasulfocarb [66952-49-6] + TX, metrafenone [220899-03-6] + TX, pencycuron [66063-05-6] + TX, phthalide [27355-22-2] + TX, polyoxins [1 1113-80-7] + TX, probenazole

[27605-76-1] + TX, propamocarb [25606-41-1] + TX, proquinazid [189278-12-4] + TX, pyroquilon [57369-32-1] + TX, quinoxyfen [124495-18-7] + TX, quintozene [82-68-8] + TX, sulphur [7704-34- 9] + TX, tiadinil [223580-51-6] + TX, triazoxide [72459-58-6] + TX, tricyclazole [41814-78-2] + TX, triforine [26644-46-2] + TX, validamycin [37248-47-8] + TX, zoxamide (RH7281 ) [156052-68-5] + TX, mandipropamid [374726-62-2] + TX, isopyrazam [881685-58-1] + TX, sedaxane [874967-67-6] + TX, 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylene-1 ,2,3,4-tetrahydro- 1 ,4-methano-naphthalen-5-yl)-amide (dislosed in WO 2007/048556) + TX, 3-difluoromethyl-1-methyl- 1 H-pyrazole-4-carboxylic acid [2-(2,4-dichlorophenyl)-2-methoxy-1-methyl-ethyl]-anriide (disclosed in WO 2008/148570) + TX, 1-[4-[4-[(5S)5-(2,6-difluorophenyl)-4,5-dihydro-1 ,2-oxazol-3-yl]-1 ,3-thiazol-2- yl]piperidin-1-yl]-2-[5-methyl-3-(trifluoromethyl)-1 H-pyrazol-1-yl]ethanone + TX, 1-[4-[4-[5-(2,6- difluorophenyl)-4,5-dihydro-1 ,2-oxazol-3-yl]-1 ,3-thiazol-2-yl]piperidin-1-yl]-2-[5-methyl-3- (trifluoromethyl)-1 H-pyrazol-1-yl]ethanone [1003318-67-9], both disclosed in WO 2010/123791 , WO 2008/013925, WO 2008/013622 and WO 2011/051243 page 20) +TX, 3-difluoromethyl-1-methyl-1 H- pyrazole-4-carboxylic acid (3',4',5'-trifluoro-biphenyl-2-yl)-amide (disclosed in WO 2006/087343) + TX, 1-methyl-2-(2,4,5-trichloro-thiophen-3-yl)-ethyl] + TX , (S)-[3-(4-Chloro-2-fluoro-phenyl)-5 -(2,4- difluoro-phenyl)-isoxazol-4-y l]-pyridin-3-yl-methanol + TX, 3-(4-Chloro-2-fluoro-phenyl)-5 -(2,4- difluoro-phenyl)-isoxazol-4-y l]-pyridin-3-yl-methanol + TX, (3-difluoromethyl-1-methyl-1 H-pyrazole-4- carboxylic acid (3',4'-dichloro-5-fluoro-1 ,1 '-biphenyl-2-yl)-amide (bixafen) + TX, (N-{2-[3-Chloro-5- (trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzanriid (fluopyram) + TX, N-[2-(1 ,3- dimethylbutyl)phenyl]-5-fluoro-1 ,3-dimethyl-1 H-pyrazole-4-carboxamide (Penflufen) + TX, 1-[4-[4-[5- (2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)- 1 H-pyrazol-1-yl]ethanone (CAS Reg.-No.: 1003318-67-9, oxathiapiprolin) + TX and 3-difluoromethyl- 1-methyl-1 H-pyrazole-4-carboxylic acid (3',4',5'-trifluoro-biphenyl-2-yl)-amide (dislosed in WO

2006/087343) + TX, flupyradifurone (CAS registry number 951659-40-8) + TX, afidopyropen (CAS registry number 915972-17-7) + TX, pasteuria penetrans and TX, pasteuria spp. + TX, bacillus firmus +TX, bacillus cereus + TX, bacillus subtilis + TX and pasteuria penetrans +TX..

The references in brackets behind the active ingredients, e.g. [3878-19-1] refer to the Chemical Abstracts Registry number. The above described mixing partners are known. Where the active ingredients are included in "The Pesticide Manual" [The Pesticide Manual - A World Compendium; Thirteenth Edition; Editor: C. D. S. TomLin; The British Crop Protection Council], they are described therein under the entry number given in round brackets hereinabove for the particular compound; for example, the compound "abamectin" is described under entry number (1 ). Where "[CCN]" is added hereinabove to the particular compound, the compound in question is included in the "Compendium of Pesticide Common Names", which is accessible on the internet [A. Wood; Compendium of Pesticide Common Names, Copyright © 1995-2004]; for example, the compound "acetoprole" is described under the internet address http://www.alanwood.net/pesticides/acetoprole.html.

Most of the active ingredients described above are referred to hereinabove by a so-called "common name", the relevant "ISO common name" or another "common name" being used in individual cases. If the designation is not a "common name", the nature of the designation used instead is given in round brackets for the particular compound; in that case, the lUPAC name, the lUPAC/Chemical Abstracts name, a "chemical name", a "traditional name", a "compound name" or a "development code" is used or, if neither one of those designations nor a "common name" is used, an "alternative name" is employed. "CAS Reg. No" means the Chemical Abstracts Registry Number.

The active ingredient mixture of the compounds of formula I selected from table P with active ingredients described above comprises a compound selected from selected from Table 1 (compounds 1.1. to 1.75) or Table A (compounds 1 to 7) and an active ingredient as described above preferably in a mixing ratio of from 100: 1 to 1 :6000, especially from 50: 1 to 1 :50, more especially in a ratio of from 20: 1 to 1 :20, even more especially from 10: 1 to 1 :10, very especially from 5:1 and 1 :5, special preference being given to a ratio of from 2: 1 to 1 :2, and a ratio of from 4:1 to 2:1 being likewise preferred, above all in a ratio of 1 :1 , or 5: 1 , or 5:2, or 5:3, or 5:4, or 4:1 , or 4:2, or 4:3, or 3:1 , or 3:2, or 2: 1 , or 1 :5, or 2:5, or 3:5, or 4:5, or 1 :4, or 2:4, or 3:4, or 1 :3, or 2:3, or 1 :2, or 1 :600, or 1 :300, or 1 : 150, or 1 :35, or 2:35, or 4:35, or 1 :75, or 2:75, or 4:75, or 1 :6000, or 1 :3000, or 1 :1500, or 1 :350, or 2:350, or 4:350, or 1 :750, or 2:750, or 4:750. Those mixing ratios are understood to include, on the one hand, ratios by weight and also, on the other hand, molar ratios.

The mixtures as described above can be used in a method for controlling pests, which comprises applying a composition comprising a mixture as described above to the pests or their environment, with the exception of a method for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body. The mixtures comprising a compound of formula I selected from selected from Tables 2 to 2400 or a compound selected from Table 3 and one or more active ingredients as described above can be applied, for example, in a single "ready-mix" form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a "tank-mix", and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the compounds of formula I selected from selected from Tables 2 to 2400 or a compound selected from Table 3 and the active ingredients as described above is not essential for working the present invention.

The compositions according to the invention are prepared in a manner known per se, in the absence of auxiliaries for example by grinding, screening and/or compressing a solid active ingredient and in the presence of at least one auxiliary for example by intimately mixing and/or grinding the active ingredient with the auxiliary (auxiliaries). These processes for the preparation of the compositions and the use of the compounds I for the preparation of these compositions are also a subject of the invention.

The application methods for the compositions, that is the methods of controlling pests of the abovementioned type, such as spraying, atomizing, dusting, brushing on, dressing, scattering or pouring - which are to be selected to suit the intended aims of the prevailing circumstances - and the use of the compositions for controlling pests of the abovementioned type are other subjects of the invention. Typical rates of concentration are between 0.1 and 1000 ppm, preferably between 0.1 and 500 ppm, of active ingredient. The rate of application per hectare is generally 1 to 2000 g of active ingredient per hectare, in particular 10 to 1000 g/ha, preferably 10 to 600 g/ha.

A preferred method of application in the field of crop protection is application to the foliage of the plants (foliar application), it being possible to select frequency and rate of application to match the danger of infestation with the pest in question. Alternatively, the active ingredient can reach the plants via the root system (systemic action), by drenching the locus of the plants with a liquid composition or by incorporating the active ingredient in solid form into the locus of the plants, for example into the soil, for example in the form of granules (soil application). In the case of paddy rice crops, such granules can be metered into the flooded paddy-field. The compositions according to the invention are also suitable for the protection of plant propagation material, for example seeds, such as fruit, tubers or kernels, or nursery plants, against pests of the abovementioned type. The propagation material can be treated with the compositions prior to planting, for example seed can be treated prior to sowing. Alternatively, the compositions can be applied to seed kernels (coating), either by soaking the kernels in a liquid composition or by applying a layer of a solid composition. It is also possible to apply the compositions when the propagation material is planted to the site of application, for example into the seed furrow during drilling. These treatment methods for plant propagation material and the plant propagation material thus treated are further subjects of the invention.

The following non-limiting examples illustrate the above-described invention in greater detail without limiting it. The compounds of the invention can be distinguished from known compounds by virtue of greater efficacy at low application rates, which can be verified by the person skilled in the art using the experimental procedures outlined in the Examples, using lower application rates if necessary, for example 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm or 0.8 ppm. Preparation examples:

The following examples describe synthesis of compounds of formula (I) and intermediates thereof.

Example P1 : Preparation of 5-chloro-1-hvdroxy-6-nitro-3H-2, 1-benzoxaborole:

To nitric acid (60 mL, 99.5 mass%) maintained at -45 to -40°C with dry ice/acetonitrile bath, 5-chloro- 1-hydroxy-3H-2, 1-benzoxaborole (5.00 g, 29.7 mmol, 99 mass%) was added portionwise (10 times 0.5 g/min) under vigorous stirring and under nitrogen atmosphere. Light exothermic observed during addition. Slow dissolution observed and the mixture turned quickly red. The mixture was stirred and maintained at -45 to -30°C for 2h. The red slurry obtained was poured in an agitated becher filled with water and ice. Precipitation of fine beige solid occurred. The becher was stored in the fridge for 1 h. The fine beige solid was filtered over a tissue and washed with water. It was then dissolved in isopropanol at 45°C and water was added dropwise to the stirred solution. Precipitation occurred. The white solid was filtered over a tissue and dried in the vacuum oven at 40°C overnight. 5-chloro-1- hydroxy-6-nitro-3H-2, 1-benzoxaborole (4.54 g, 20.8 mmol, 98 mass%, 71 % Yield) was recovered as a beige solid (melting point > 200°C).

H NMR (400 MHz, DMSO-d₆) δ ppm 5.08 (s, 2 H), 7.88 (s, 1 H), 8.31 (s, 1 H), 9.62 (s, 1 H)

B NMR (128 MHz, DMSO-d₆) δ ppm 32 (br. s., 1 B)

MS [M-H]^" 21 1/212/214 (rt 0.77 min)

Example P2a: Preparation of 6-amino-5-chloro-1-hvdroxy-3H-2, 1-benzoxaborole:

A solution of 5-chloro-1-hydroxy-6-nitro-3H-2, 1-benzoxaborole (0.20 g, 0.94 mmol, 98 mass%) in THF (19 mL, 99.8 mass%) was passed in the H-Cube continuous flow hydrogenation machine (settings: solution concentration 0.050 mmol/mL, flowrate 1 .0 mL/min, cartridge temperature 60°C, exit pressure 50 bar) with Raney Nickel standard cartridge. The solution obtained was evaporated and subject to flash chromatography over silicagel with ethyl acetate as eluent. Solvent was evaporated. 6-amino-5- chloro-1-hydroxy-3H-2, 1-benzoxaborole (138 mg, 0.60 mmol, 97 mass%, 63% Yield) was recovered as a brown solid (melting point > 200°C).

H NMR (400 MHz, DMSO-d₆) δ ppm 4.82 (s, 2 H), 5.25 (s, 2 H), 7.1 1 (s, 1 H), 7.25 (s, 1 H), 9.06 (s, 1 H)

B NMR (128 MHz, DMSO-d₆) δ ppm 33 (br. s., 1 B)

MS [M+H]⁺ 183/184/186 (rt 0.60 min)

Example P2b: Preparation of 6-amino-5-chloro-1-hvdroxy-3H-2, 1-benzoxaborole:

5-chloro-1-hydroxy-6-nitro-3H-2, 1-benzoxaborole (23.50 g, 99.12 mmol, 90 mass%) was dissolved in ethanol (200 mL, 99.9 mass%) and water (10 mL, 100 mass%) at 35°C and iron (16.77 g, 3.0 equiv., 297.4 mmol, 99 mass%) was added to the vigorously stirred solution followed by calcium chloride (17.00 g, 1.5 equiv., 148.7 mmol, 97 mass%) crushed in a morter. The mixture was vigorously stirred at 75°C for 6h. The mixture was poured in a flask with isolute adsorbent and the solvents were fully evaporated. The residue obtained was subject to manual column chromatography over silicagel with ethyl acetate/methanol 1 :0 to 95:5 as eluant. 6-amino-5-chloro-1-hydroxy-3H-2, 1-benzoxaborole (9.23 g, 47.8 mmol, 95 mass%, 48.2% Yield) was recovered as a red solid (melting point > 200°C).

B NMR (128 MHz, DMSO-d₆) δ ppm 33 (br. s., 1 B)

MS [M+H]⁺ 183/184/186 (rt 0.60 min)

Example P3: Preparation of N-(5-chloro-1-hvdroxy-3H-2, 1-benzoxaborol-6-yl)-4-cyano-benzamide (compound Y.074):

6-amino-5-chloro-1-hydroxy-3H-2,1-benzoxaborole (85.6 mg, 0.45 mmol, 97 mass%) and diisopropylethylamine (0.16 mL, 2.0 equiv., 0.90 mmol, 99 mass%) were stirred in THF (2.5 mL, 99.8 mass%) and a solution of 4-cyanobenzoyl chloride (80 mg, 1.05 equiv., 0.47 mmol, 99 mass%) in THF (2.0 mL, 99.8 mass%) was added dropwise. The mixture was stirred at 23°C for 18h. The mixture was evaporated and the residue was purified by reverse phase column chromatography. N-(5-chloro-1- hydroxy-3H-2, 1-benzoxaborol-6-yl)-4-cyano-benzamide (68 mg, 0.22 mmol, 99 mass%, 48% Yield) was recovered as a white solid (melting point > 200°C).

H NMR (400 MHz, DMSO-d₆) δ ppm 5.03 (s, 2 H), 7.68 (s, 1 H), 7.90 (s, 1 H), 8.06 (dt, J=8.5, 1.8 Hz, 2 H), 8.16 (dt, J=8.5, 1 .7 Hz, 2 H), 9.41 (s, 1 H), 10.43 (s, 1 H)

B NMR (128 MHz, CHL OROFORM-d) δ ppm 32 (br. s., 1 B)

MS [M-H]^" 310/311/313 (rt 0.79 min)

Example P4: Preparation of N-(5-chloro-1-hvdroxy-3H-2, 1-benzoxaborol-6-yl)-2-(2,4- dichlorophenvDpentanamide (compound Y.062 :

6-amino-5-chloro-1-hydroxy-3H-2,1-benzoxaborole (97.0 mg, 0.50 mmol, 95 mass%) was suspended in acetonitrile (5.0 mL, 99.7 mass%) and diisopropylethylamine (0.10 mL, 1.2 equiv., 0.60 mmol, 99 mass%) was added. The mixture was stirred at 23°C for 5 min and 2-(2,4-dichlorophenyl)pentanoyl chloride (0.14 g, 1 .05 equiv., 0.52 mmol, 98 mass%) was added dropwise. The mixture was stirred for 18h at 30°C. The mixture was evaporated, poured in 1 M HCI and extracted with ethyl acetate. Combined organics were dried over sodium sulfate and evaporated under reduced pressure. The crude was subject to flash chromatography over silicagel with cyclohexane/ethyl acetate 85: 15 to 50:50 as eluant. N-(5-chloro-1-hydroxy-3H-2, 1-benzoxaborol-6-yl)-2-(2,4-dichlorophenyl)pentanamide (1 15 mg, 0.28 mmol, 99 mass%, 56% Yield) was obtained as a white solid (melting point: 89-109°C). H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.77 - 0.93 (m, 1 H), 1.27 - 1.51 (m, 3 H), 1.70 - 1.95 (m, 1 H), 2.12 - 2.35 (m, 1 H), 3.86 (br. s., 1 H), 4.07 - 4.19 (m, 1 H), 5.00 (s, 2 H), 5.67 (br. s., 1 H), 7.21 - 7.36 (m, 2 H), 7.40 - 7.52 (m, 2 H), 7.76 (d, J=17.6 Hz, 1 H), 8.58 (s, 1 H)

B NMR (128 MHz, CHLOROFORM-d) δ ppm 32 (br. s., 1 B)

MS [M+H]⁺ 41 1/412/413/414/415/416 (rt 1.14 min)

The following Table illustrates the invention

Compounds of formula IA

Table X:

Table 1 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA:

wherein, R-i is F, n is 0, W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined Table V. Table 2: This table discloses the 264 compounds T1.001 to T1 .264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 3: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 4: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 5: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is n-propyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 6: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is c-propyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 7: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is n-butyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 8: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is s-butyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 9: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is i-butyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 10: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is t-butyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 1 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 12: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both ethyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 13: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃form together with the carbon attached a cyclopropyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 14: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃form together with the carbon attached a cyclopentyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 15: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ and R₃form together with the carbon attached a cyclohexyl, n is 1 , W is a bond, A is A to A₆ and A R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 16: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ and R₃ are both hydrogen, n is 2, W is a bond, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 17: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ and R₃ are both hydrogen, n is 3, W is a bond, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 18: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ is methyl, R₃ is H, n is 2, W is a bond, A is A to A6 and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 19: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ and R₃ are both hydrogen, n is 1 , W is O, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 20: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ is methyl, R₃ is H, n is 1 , W is O, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 21 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ is ethyl, R₃ is H, n is 1 , W is O, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 22: This table discloses the 264 compounds T1.001 to T1 .264 of the formula IA, wherein, R is F, R₂ and R₃ are both methyl, n is 1 , W is O, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 23: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂0, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 24: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ is methyl, R₃ is H, n is 1 , W is CH₂0, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 25: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂0, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 26: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ and R₃ are both methyl, n is 1 , W is CH₂0, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 27: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R is F, R₂ and R₃ are both hydrogen, n is 1 , W is S, A is A to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 28: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 29: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 30: This table discloses the 264 compounds T1.001 to T1 .264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is S, A is A-i to A6 and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 31 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 32: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is CH₂S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 33: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 34: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is CH₂S, A is Ai to A₆ and Α·,₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 35: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 36: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 37: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 38: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 39: This table discloses the 264 compounds T1 .001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 40: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 41 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 42: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 43: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 44: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is CH₂NH, A is A-i to A6 and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 45: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 46: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is CH₂NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 47: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂NMe, A is Ai to A₆ and Α·,₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 48: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is CH₂NMe, A is Ai to A₆ and Α·,₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 49: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂NMe, A is Ai to Ae and Α·,₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 50: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is CH₂NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 51 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂NOMe, A is Ai to A₆ and Α·,₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 52: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is CH₂NOMe, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 53: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂NOMe, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 54: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is CH₂NOMe, A is Ai to A₆ and Ai₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 55: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is -CH₂-ON=CH, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 56: This table discloses the 264 compounds T1.001 to T1 .264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is -CH₂-ON=CH, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 57: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is -CH₂-ON=CH, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 58: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is -CH₂-ON=CH, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 59: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both hydrogen, n is 1 , W is -CH₂-ON=C(CH₃), A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 60: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is -CH₂-ON=C(CH₃), A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 61 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is -CH₂-ON=C(CH₃), A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 62: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is -CH₂-ON=C(CH₃), A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 63: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is methyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 64: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 65: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is n-propyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 66: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is c-propyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 67: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is n-butyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 68: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is s-butyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 69: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is i-butyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 70: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ is t-butyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 71 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both methyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 72: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃ are both ethyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 73: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃form together with the carbon attached a cyclopropyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 74: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃form together with the carbon attached a cyclopentyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 75: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is F, R₂ and R₃form together with the carbon attached a cyclohexyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 76: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is

F, n is 0, W is CH=CH, A is Ai to A₆ and Α·,₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 77: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is

F, n is 0, W is CH(CH₃)=CH, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 78: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is

F, n is 0, W is 1 ,2-cyclopropane, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 79: This table discloses the 264 compounds T1.001 to T1 .264 of the formula IA,

wherein, R-i is CI, n is 0, W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in

Table V.

Table 80: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 81 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 82: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 83: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is n-propyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 84: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is c-propyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 85: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is n-butyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 86: This table discloses the 264 compounds T1.001 to T1 .264 of the formula IA, wherein, R-i is CI, R₂ is s-butyl, R₃ is H, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 87: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is i-butyl, R₃ is H, n is 1 , W is a bond, A is A-i to A6 and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 88: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is t-butyl, R₃ is H, n is 1 , W is a bond, A is A-i to A6 and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 89: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 90: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both ethyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 91 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃form together with the carbon attached a cyclopropyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 92: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃form together with the carbon attached a cyclopentyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 93: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃form together with the carbon attached a cyclohexyl, n is 1 , W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 94: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 2, W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 95: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 3, W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 96: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 2, W is a bond, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 97: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is O, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 98: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is O, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 99: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is O, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 100: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is O, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 101 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂0, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 102: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is CH₂0, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 103: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂0, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 104: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is CH₂0, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 105: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 106: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 107: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 108: This table discloses the 264 compounds T1 .001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 109: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 10: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is CH₂S, A is A-i to A6 and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 1 1 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 12: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is CH₂S, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 13: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 14: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 15: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 16: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 17: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 18: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 19: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 120: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is NMe, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 121 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂NH, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 122: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is CH₂NH, A is Ai to A₆ and Ai₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 123: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, Ri is CI, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂NH, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 124: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is CH₂NH, A is Ai to A₆ and Ai₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 125: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂NMe, A is Ai to A₆ and Α·,₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 126: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is CH₂NMe, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 127: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂NMe, A is Ai to A₆ and Ai₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 128: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is CH₂NMe, A is Ai to A₆ and Α·,₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 129: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is CH₂NOMe, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 130: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is CH₂NOMe, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 131 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂NOMe, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 132: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is CH₂NOMe, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 133: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is CH=NO, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 134: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is CH=NO, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 135: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is CH=NO, A is A-, to Ae and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 136: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is CH=NO, A is Ai to A₆ and Ai₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 137: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both hydrogen, n is 1 , W is CH(CH₃)=NO, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 138: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is CH(CH₃)=NO, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 139: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is CH(CH₃)=NO, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 140: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is CH(CH₃)=NO, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 141 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is methyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 142: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is ethyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 143: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is n-propyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 144: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is c-propyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 145: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is n-butyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1. Table 146: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is s-butyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 147: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is i-butyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 148: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ is t-butyl, R₃ is H, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 149: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both methyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 150: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃ are both ethyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 151 : This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃form together with the carbon attached a cyclopropyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 152: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, R₂ and R₃form together with the carbon attached a cyclopentyl, n is 1 , W is CH₂, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 153: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is

CI, R₂ and R₃form together with the carbon attached a cyclohexyl, n is 1 , W is CH₂, A is A-i to A₆ and

A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 154: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is

CI, n is 0, W is CH=CH, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 155: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is

CI, n is 0, W is CH(CH₃)=CH, A is A-, to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 156: This table discloses the 264 compounds T1.001 to T1.264 of the formula IA, wherein, R-i is CI, n is 0, W is 1 ,2-cyclopropane, A is A-i to A₆ and A₁₃, R_a, R_b, R_c, R_d and R_e are as defined in Table 1.

Table 1 :

The table 1 discloses specific meanings of the substituents A, R_a, R_b, R_c, R_d, R_e

-59-

*

Table 2:

Table 3 : Characterising data:

Table 3 shows selected melting point and selected NMR data for compounds of Table 1 .

CDCI₃/D₂O and DMSO are used as solvents for NMR 400 MHz measurements. No attempt is made to list all characterising data in all cases. ln Table 3 and throughout the description that follows, temperatures are given in degrees Celsius; "NMR" means nuclear magnetic resonance spectrum; MS stands for mass spectrum; "%" is per cent by weight, unless corresponding concentrations are indicated in other units. The following abbreviations are used throughout this description:

5

m.p. = melting point b.p.= boiling point.

S = singlet br = broad

d = doublet dd = doublet of doublets

t = triplet q = quartet

m = multiplet ppm = parts per million

The following LC-MS method was used to characterize the compounds:

ACQUITY SQD Mass Spectrometer from Waters (Single quadrupole mass spectrometer)

lonisation method: Electrospray

l Oppolarity: positive ions

Capillary (kV) 3.00, Cone (V) 20.00, Extractor (V) 3.00, Source Temperature (°C) 150, Desolvation

Temperature (°C) 400, Cone Gas Flow (L/Hr) 60, Desolvation Gas Flow (L/Hr) 700

Mass range: 100 to 800 Da

DAD Wavelength range (nm): 210 to 400

15

Method Waters ACQUITY UPLC with the following HPLC gradient conditions

(Solvent A: Water/Methanol 9:1 ,0.1 % formic acid and Solvent B: Acetonitrile,0.1 % formic acid )

Time (minutes) A (%) B (%) Flow rate (ml/min)

0 100 0 0.75

20 2.5 0 100 0.75

2.8 0 100 0.75

3.0 100 0 0.75

Type of column: Waters ACQUITY UPLC HSS T3; Column length: 30 mm; Internal diameter of column: 2.1 mm; Particle Size: 1.8 micron; Temperature: 60°C.

25

The characteristic values obtained for each compound were the retention time ("R_t", recorded in minutes) and the molecular ion as listed in Table 3.

30 Table 3: Physical data of compounds of formula I:

Cpd No. m.p. (°C) MS [M+H]⁺ R_t (min) 1 H-NMR data: ppm (multiplicity/number of Hs)

Y.001 >240 286 1.08

Y.002 340 1.30 Cpd No. m.p. (°C) MS [M+H]⁺ R_t (min) 1 H-NMR data: ppm (multiplicity/number of Hs)

Y.003 216-221 298 1.23

Y.004 189-199 340 1.39

Y.005 322 1.26

Y.006 320 1.20

Y.007 306 1.23

Y.008 333 1.16

Y.009 320 1.65

Y.010 196-200 352 1.40

Y.01 1 347 1.31

Y.012 374 1.35

Y.013 324 1.16

Y.014 273 1.16

Y.015 291 0.90

Y.016 374 1.65

Y.017 362 1.28

Y.018 341 1.1 1

Y.019 440 1.50

Y.020 396 1.76

Y.021 362 1.56

Y.022 374 1.30

Y.023 370 1.26

Y.024 332 1.33

Y.025 362 1.08

Y.026 208-21 1 306 1.22

Y.027 312 1.28

Y.028 339 1.44

Y.029 344 1.28

Y.030 277 1.03 Cpd No. m.p. (°C) MS [M+H]⁺ R_t (min) 1 H-NMR data: ppm (multiplicity/number of Hs)

Y.031 380 1.38

Y.032 405 1.35

Y.033 328 1.12

Y.034 326 1.25

Y.035 308 1.19

Y.036 308 1.16

Y.037 332 1.59

Y.038 326 1.08

Y.039 312 1.34

Y.040 328 1.46

Y.041 342 1.24

Y.042 308 1.01

Y.043 340 1.32

Y.044 290 1.18

Y.045 186-189 324 1.34

Y.046 326 1.08

Y.047 308 1.16

Y.048 308 1.16

Y.049 340 1.14

Y.050 308 1.17

Y.051 316 1.30

Y.052 340 1.24

Y.053 397 1.15

Y.054 353 1.23

Y.055 378 1.47

Y.056 304 1.10

Y.057 215-218 304 1.12

Y.058 375 1.40 Cpd No. m.p. (°C) MS [M+H]⁺ R_t (min) 1 H-NMR data: ppm (multiplicity/number of Hs)

Y.059 158-160 316 1.28

Y.060 292 1.03

Y.061 240 0.76

Y.062 89-109 412/414 1.14 ( CHL OROFORM-d) : 0.77 - 0.93 (m, 1 H), 1.27 - 1.51 (m, 3 H), 1.70 - 1.95 (m, 1 H), 2.12 - 2.35 (m, 1 H), 3.86 (br. s., 1 H), 4.07 - 4.19 (m, 1 H), 5.00 (s, 2 H), 5.67 (br. s., 1 H), 7.21 - 7.36 (m, 2 H), 7.40 - 7.52 (m, 2 H), 7.76 (d, J=17.6 Hz, 1 H), 8.58 (s, 1 H)

Y.063 220-226 302

Y.064 207-210 338

Y.065 210-215 340

Y.066 solid 340/342 0.99 (METHANOL-d₄): 5.07 (s, 2 H), 7.36 - 7.49 (m, 2

H), 7.57 (s, 1 H), 7.93 (t, J=8.3 Hz, 1 H), 8.21 (s, 1 H)

Y.067 >235 368/370 0.99

Y.068 >240 320/322 0.85

Y.069 >235 322/324/326 0.90

Y.070 145-147 332/334 0.93

Y.071 >230 323 0.98

Y.072 >230 339/341 1.05

Y.073 >200 297 0.73

Y.074 >200 313/315 0.79 (DMSO-d₆): 5.03 (s, 2 H), 7.68 (s, 1 H), 7.90 (s, 1

H), 8.06 (dt, J=8.5, 1 .8 Hz, 2 H), 8.16 (dt, J=8.5, 1.7 Hz, 2 H), 9.41 (s, 1 H), 10.43 (s, 1 H)

Y.075 >240 399/401 1.04

Y.076 >240 360/362 0.80

Y.077 >200 not dedected 0.83

Y.078 >200 288/290 0.82

Y.079 >200 342 0.82

Y.080 21 1-213 360/362 0.81 Cpd No. m.p. (°C) MS [M+H]⁺ R_t (min) 1 H-NMR data: ppm (multiplicity/number of Hs)

Y.081 >240 320/322 0.84

Y.082 212-216 274/276 0.78

Y.083 180-190 260/262 0.70

Y.084 145-160 348/350 0.94

Y.085 >240 320/322 0.78

Y.086 120-131 348/350 0.97

Y.087 236-240 392/394 0.84

Y.088 130-135 405/407 1.09

Y.089 121-125 332/334 0.95

Y.090 >200 334/336 0.91

Y.091 >200 318/320 0.91

Y.092 190-200 366/368 1.00

Y.093 >215 385/86/88/90 1.07

Y.094 >210 363/365 0.89

Y.095 130-145 346/348 1.00

Y.096 >200 366/368 0.93

Y.097 314/316 1.06

Y.098 432/434 1.07

Y.099 380/382 1.08

Y.100 185-195 256/258 0.70

Y.101 160-170 350/352 0.95

Y.102 121-125 332/334 0.95

Y.103 200-204 374/376 0.90

Y.104 137-140 366/368 1.01

Y.105 >200 321/323 0.85

Y.106 solid 305 0.80

Y.107 solid 337/339 0.92

Y.108 solid 320/321/323 0.87 Cpd No. m.p. (°C) MS [M+H]⁺ R_t (min) 1 H-NMR data: ppm (multiplicity/number of Hs)

Y.109 solid 302/303/305 0.83

Y.1 10 solid 287 0.78

Y.1 1 1 solid 337/339 0.91

Y.1 12 solid 321/323 0.87

Y.1 13 solid 255/257 0.66

Y.1 14 solid 239 0.58

Y.1 15 solid 283/285 0.81

Y.1 16 solid 267 0.76

Y.1 17 solid 289/291 0.70

Y.1 18 solid 273/275 0.64

Y.1 19 solid 283/285 0.82

Y.120 solid 267 0.77

Y.121 solid 318/320 1.07

Y.122 solid not dedected 0.90

Y.123 180-190 not dedected 0.90

Y.124 242/244 0.71

Y.125 >200 324/326 0.81

Formulation examples for compounds of formula (I):

Example F-1.1 to F-1.2: Emulsifiable concentrates

Emulsions of any desired concentration can be prepared by diluting such concentrates with water. Example F-2: Emulsifiable concentrate

Emulsions of any desired concentration can be prepared by diluting such concentrates with water. Examples F-3.1 to F-3.4: Solutions

The novel compound is dissolved in dichloromethane, the solution is sprayed onto the carrier and the solvent is then removed by distillation under vacuum.

Examples F-5.1 and F-5.2: Dusts

Components F-5.1 F-5.2 A compound selected from the Tables 2 to 2400 or a compound selected from Table 3 2% 5% highly dispersed silicic acid 1 % 5%

Talcum 97% -

Kaolin - 90%

Ready for use dusts are obtained by intimately mixing all components. Examples F-6.1 to F-6.3: Wettable powders

Components F- F- F- 6.1 6.2 6.3

A compound selected from the Tables 2 to 2400 or a compound selected from 25% 50% 75% Table 3

sodium lignin sulfonate 5% 5% - sodium lauryl sulphate 3% - 5% sodium diisobutylnaphthalene sulfonate 6% 10% - octylphenolpolyethylene glycol ether 2%

(7 to 8 mol ethylenoxy units)

highly dispersed silicic acid 5% 10% 10%

Kaolin 62% 27% -

All components are mixed and the mixture is thoroughly ground in a suitable mill to give wettable powders which can be diluted with water to suspensions of any desired concentration.

Example F7: Flowable concentrate for seed treatment

The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion. BIOLOGICAL EXAMPLES: FUNGICIDAL ACTION:

1 Phytophthora infestans I tomato / leaf disc preventative (late blight)

Tomato leaf disks were placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water at an application rate of 200ppm. The leaf disks were inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf disks were incubated at 16°C and 75% relative humidity under a light regime of 24 h darkness followed by 12/12 h (light/dark) in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (5 - 7 days after application). The following compounds gave at least 80% control of Phytophthora infestans: Y.001 , Y.042, Y.044, Y.045, Y.047, Y.049, Y.051 , Y.052, Y.053, Y.054, Y.056, Y.057, Y.059, Y.081 , Y.082, Y.083, Y.103, Y.125.

2 Plasmopara viticola I grape / leaf disc preventative (late blight)

Grape vine leaf disks were placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks were inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf disks were incubated at 19°C and 80% relative humidity under a light regime of 12/12 h (light/dark) in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (6 - 8 days after application). The following compounds gave at least 80% control of Plasmopara viticola Y.001 , Y.002, Y.003, Y.004, Y.005, Y.006, Y.007, Y.008, Y.010, Y.01 1 , Y.012, Y.013, Y.016, Y.021 , Y.026, Y.027, Y.028, Y.029, Y.032, Y.041 , Y.042, Y.043, Y.045, Y.049, Y.050, Y.052, Y.053, Y.054, Y.056, Y.057, Y.058, Y.059, Y.063, Y.064, Y.065, Y.067, Y.068, Y.069, Y.070, Y.076, Y.077, Y.078, Y.079, Y.080, Y.081 , Y.082, Y.083, Y.084, Y.085, Y.086, Y.087, Y.089, Y.090, Y.091 , Y.092, Y.094, Y.095, Y.098, Y.101 , Y.102, Y.103, Y.123, Y.125.

4 Puccinia recondita f. sp. tritici I wheat / leaf disc preventative (Brown rust):

Wheat leaf segments cultivated variety (cv) Kanzler were placed on agar in 24-well plates and sprayed with formulated test compound diluted in water at an application rate of 200ppm. The leaf disks were inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf segments were incubated at 19°C and 75% relative humidity under a light regime of 12/12 h (light/dark) in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf segments (7 - 9 days after application). The following compounds gave at least 80% control of Puccinia recondita f. sp. Tritici: Y.010, Y.01 1 , Y.016, Y.017, Y.031 , Y.064, Y.067, Y.069, Y.070, Y.076, Y.081 , Y.086, Y.089, Y.095, Y.101 , Y.102, Y.104.

5 Phaeosphaeria nodorum (Septoria nodorum) / wheat / leaf disc preventative (Glume blotch): Wheat leaf segments cv Kanzler were placed on agar in a 24-well plate and sprayed with formulated test compound diluted in water at an application rate of 200ppm. The leaf disks were inoculated with a spore suspension of the fungus 2 days after application. The inoculated test leaf disks were incubated at 20°C and 75% relative humidity under a light regime of 12/12 h (light/dark) in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (5 - 7 days after application). The following compounds gave at least 80% control of Phaeosphaeria nodorum Y.082, Y.104, Y.125.

7 Alternaria solani I tomato / leaf disc (early blight)

Tomato leaf disks cultivated variety (cv.) Baby were placed on agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water at an application rate of 200ppm. The leaf disks were inoculated with a spore suspension of the fungus 2 days after application. The inoculated leaf disks were incubated at 23°C/21°C (day/night) and 80% relative humidity under a light regime of 12/12 h (light/dark) in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears on untreated check disk leaf disks (5 - 7 days after application). The following compounds gave at least 80% control of Alternaria solani: Y.055.

8 Maqnaporthe grisea (Pyricularia oryzae) I rice / leaf disc preventative (Rice Blast):

Rice leaf segments cv. Ballila were placed on agar in multiwell plate (24-well format) and sprayed with the formulated test compound diluted in water at an application rate of 200ppm. The leaf segments were inoculated with a spore suspension of the fungus 2 days after application. The inoculated leaf segments were incubated at 22°C and 80% rh under a light regime of 24 h darkness followed by 12/12 h (light/dark) in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf segments (5 - 7 days after application). The following compounds gave at least 80% control of Magnaporthe grisea Y.029, Y.099.

9 Pythium ultimum I liquid culture (seedling damping off)

Mycelia fragments and oospores of a newly grown liquid culture of the fungus were directly mixed into nutrient broth (potato dextrose broth). After placing a DMSO solution of test compound into a 96- well format microtiter plate at an application rate of 200ppm, the nutrient broth containing the fungal mycelia/spore mixture was added. The test plates were incubated at 24°C and the inhibition of growth was determined photometrically 2-3 days after application. The compounds gave at least 80% control of Pythium ultimo: Y.001, Y.002, Y.003, Y.004, Y.005, Y.006, Y.007, Y.008, Y.009, Y.010, Y.011, Y.012, Y.013, Y.014, Y.015, Y.016, Y.017, Y.018, Y.019, Y.020, Y.021, Y.022, Y.023, Y.024, Y.025, Y.026, Y.027, Y.028, Y.029, Y.030, Y.031, Y.032, Y.033, Y.041, Y.042, Y.043, Y.044, Y.045, Y.047, Y.048, Y.049, Y.050, Y.051, Y.052, Y.053, Y.054, Y.056, Y.057, Y-058, Y.059, Y.061, Y.063, Y.064, Y.065, Y.067, Y.068, Y.069, Y.070, Y.071, Y.073, Y.074, Y.076, Y.077, Y.078, Y.079, Y.080, Y.081, Y.082, Y.083, Y.084, Y.085, Y.086, Y.087, Y.088, Y.089, Y.090, Y.091, Y.092, Y.093, Y.094, Y.095, Y.096, Y.097, Y.100, Y.101, Y.102, Y.103, Y.104, Y.105, Y.106, Y.108, Y.109, Y.110, Y.113, Y.114, Y.115, Y.116, Y.117, Y.118, Y.119, Y.120, Y.122, Y.123, Y.124, Y.125.

10 Botryotinia fuckeliana (Botrytis cinerea) I liguid culture (Gray mould):

Conidia of the fungus from cryogenic storage were directly mixed into nutrient broth (Vogels broth). After placing a DMSO solution of test compound into a 96-well microtiter plate at an application rate of 200ppm, the nutrient broth containing the fungal spores was added. The test plates were incubated at 24°C and the inhibition of growth was determined photometrically 3-4 days after application. The following compounds gave at least 80% control of Botryotinia fuckeliana: Y.033, Y.088, Y.099, Y.100, Y.122.

11 Glomerella lagenarium (Colletotrichum lagenarium) I liquid culture (Anthracnose) :

Conidia of the fungus from cryogenic storage were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a DMSO solution of test compound into a 96-well microtiter plate at an application rate of 200ppm, the nutrient broth containing the fungal spores was added. The test plates were incubated at 24°C and the inhibition of growth was measured photometrically 3-4 days after application. The following compounds gave at least 80% control of Glomerella lagenarium : Y.002, Y.005, Y.010, Y.01 1 , Y.013, Y.014, Y.016, Y.020, Y.021 , Y.026, Y.029, Y.033, Y.042, Y.049, Y.050, Y.051 , Y.052, Y.053, Y.054, Y.059, Y.062, Y.064, Y.067, Y.069, Y.078, Y.083, Y.086, Y.088, Y.089, Y.090, Y.091 , Y.095, Y.097, Y.099, Y.102, Y.104, Y.107, Y.108, Y.121 , Y.122, Y.125.

12 Mycosphaerella arachidis (Cercospora arachidicola) I liquid culture (early leaf spot):

Conidia of the fungus from cryogenic storage were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a DMSO solution of test compound into a 96-well microtiter plate at an application rate of 200ppm, the nutrient broth containing the fungal spores was added. The test plates were incubated at 24°C and the inhibition of growth was determined photometrically 4-5 days after application. The compounds gave at least 80% control of Mycosphaerella arachidis: Y.003, Y.020, Y.033, Y.062, Y.063, Y.065, Y.070, Y.078, Y.082, Y.083, Y.084, Y.086, Y.089, Y.090, Y.091 , Y.095, Y.097, Y.099, Y.102, Y.104, Y.121 , Y.122.

13 Mycosphaerella graminicola (Septoria tritici) I liquid culture (Septoria blotch):

Conidia of the fungus from cryogenic storage were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a DMSO solution of test compound into a 96-well microtiter plate at an application rate of 200ppm, the nutrient broth containing the fungal spores was added. The test plates were incubated at 24°C and the inhibition of growth was determined photometrically 4-5 days after application. The following compounds gave at least 80% control of Mycosphaerella graminicola: Y.020, Y.033, Y.062, Y.083, Y.089, Y.089, Y.095, Y.097, Y.102, Y.104, Y.107, Y.108, Y.120, Y.121 , Y.122.

14 Gaeumannomyces graminis l liquid culture (Take-all of cereals):

Mycelial fragments of the fungus from cryogenic storage were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a DMSO solution of test compound into a 96-well microtiter plate at an application rate of 200ppm, the nutrient broth Cp.33, containing the fungal spores is added. The test plates were incubated at 24°C and the inhibition of growth was determined photometrically 4- 5 days after application. The compounds gave at least 80% control of Gaeumannomyces: Y.005, Y.008, Y.010, Y.011, Y.013, Y.014, Y.016, Y.020, Y.021, Y.022, Y.028, Y.029, Y.031, Y.033, Y.042, Y.043, Y.045, Y.050, Y.051, Y.052, Y.053, Y.059, Y.062, Y.064, Y.067, Y.069, Y.070, Y.071, Y.076, Y.078, Y.079, Y.080, Y.082, Y.083, Y.086, Y.090, Y.092, Y.093, Y.097, Y.098, Y.099, Y.101, Y.104, Y.125.

15 Monographella nivalis (Microdochium nivale) I liquid culture (foot rot cereals):

Conidia of the fungus from cryogenic storage were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a DMSO solution of test compound into a 96-well microtiter plate at an application rate of 200ppm, the nutrient broth containing the fungal spores was added. The test plates were incubated at 24°C and the inhibition of growth was determined photometrically 4-5 days after application. The compounds gave at least 80% control of Monographella nivalis: Y.010, Y.01 1 , Y.014, Y.016, Y.020, Y.021 , Y.022, Y.023, Y.024, Y.029, Y.031 , Y.032, Y.033, Y.042, Y.049, Y.050, Y.051 , Y.067, Y.078, Y.082, Y.083, Y.085, Y.086, Y.088, Y.089, Y.090, Y.091 , Y.093, Y.095, Y.097, Y.098, Y.099, Y.101 , Y.102, Y.104, Y.108, Y.122, Y.123, Y.125.

16 Fusarium culmorum I liquid culture (Head blight):

Conidia of the fungus from cryogenic storage were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a (DMSO) solution of the test compounds into a microtiter plate (96-well format), the nutrient broth containing the fungal spores was added. The test plates were incubated at 24°C and the inhibition of growth was determined visually 3-4 days after application. The following compounds gave at least 80% control of Fusarium culmorum: Y.022, Y.026, Y.029, Y.033, Y.088, Y.089, Y.090, Y.091 , Y.099, Y.102, Y.104, Y.125.

17 Thanatephorus cucumeris (Rhizoctonia solani) I liquid culture (foot rot, dampinq-off):

Mycelia fragments of a newly grown liquid culture of the fungus were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a DMSO solution of the test compounds into a 96- well microtiter plate at an application rate of 200ppm, the nutrient broth containing the fungal material was added. The test plates were incubated at 24°C and the inhibition of growth was determined photometrically 3-4 days after application. The following compounds gave at least 80% control of Thanatephorus cucumeri: Y.008, Y.011, Y.026, Y.029, Y.045, Y.067, Y.069, Y.083, Y.088, Y.104, Y.125.

Claims

Claims:

wherein

R-i is fluorine, chlorine, bromine, cyano, Ci-C₄alkyl or d-C₄haloalkyl;

R₂ and R₃ are, independently from each other hydrogen, halogen, Ci-C₆alkyl, C₂-C₆alkenyl, C₃- C₆alkinyl, C₃-C₆cycloalkyl, C₃-C₆alkinyl, phenyl or R₂ and R₃ may form a cyclic ring;

W is oxygen, sulphur, nitrogen, Ci-C₆alkylamino, -C₁-C₄alkyl-0-N=CH-, -0-N=CH-, -0-N=C-(d- C₄alkyl), Ci-C₆alkylene, C₂-C₆alkenylene, C₃-C₆alkinylene, C₃-C₆cycloalkyl, or a direct bond;

A is an oprtionally substituted aryl or a optionally substituted heteroaryl wherein the optional substituents for the oprtionally substituted aryl and a optionally substituted heteroary groups are selected from F, CI, Br, I, -OH, -CN, nitro, a oxo substituent, -Ci_₄alkoxy, -Ci_₄ alkylthio, C₁_₄alkyl, C₂_ ₄alkenyl, C₂.₄alkenyl, C₂.₄alkynyl, -C(0)H, -C(0)(Ci_4 alkyl), -C(0)(Ci_4 alkoxy), -C(0)NH₂, - C(0)NH(d_₄ alkyl), -C(0)N(d_₄ alkyl)(d_₄ alkyl), -OC(0)NH(d_₄ alkyl), -OC(0)N(d_₄ alkyl)(d_₄ alkyl),-NHC(0)(d_₄ alkyl),- NHC(0)(d_₄ alkoxy), -N(C^ alkyl )C(0)(d_₄ alkyl), -N(d_₄ alkyl )C(0)(d_₄ alkoxy), -OC(O) (d_₄ alkyl), -OC(0)(d_₄ alkoxy), -Si(C^ alkyl)₃, -Si(d_₄ alkoxy)₃, C₆.₁₀aryl, C₆.₁₀aryloxy, C₆-ioarylthio, C₆-ioheteroaryl, -(Ci_₈ - perhaloalkyl) , arylC₂.₆alkynyl, -C₂.₆alkenyl, heteroarylC₂.₆alkynyl, -C₂.₆alkenyl, C₃.₈cycloalkyl , -NR⁸R⁹ where R⁸ and R⁹ are independently H, -Ci_₄alkyl -C₂.₄alkenyl, -C₂. ₄alkynyl or combine with the interjacent nitrogen to form a five- or six-membered ring which may comprise one or two or three heteroatoms (one or two N, O or S atoms in addition to the interjacent nitrogen atom), in which case the heterocyclic ring is unsubstituted or the heterocyclic ring is substituted by one or two oxo substituent , C₁_₄alkyl groups, -C₂.₄alkenyl or substituted -C₂.₄alkenyl, - C₂.₄alkynyl or substituted -C₂.₄alkynyl, -C(0)H, -C(0)(d_₄ alkyl), -C(0)(d_₄ alkoxy), -C(0)NH₂, - C(0)NH(d_₄ alkyl), -C(0)N(d_₄ alkyl)(d_₄ alkyl), -OC(0)NH(d_₄ alkyl), -OC(0)N(d_₄ alkyl)(d_₄ alkyl),-NHC(0)(d_₄ alkyl),- NHC(0)(d_₄ alkoxy), -N(C^ alkyl )C(0)(d_₄ alkyl), -N(d_₄ alkyl )C(0)(d_₄ alkoxy), -OC(O) (d_₄ alkyl), -OC(0)(d_₄ alkoxy), -Si(C^ alkyl)₃, -Si(d_₄ alkoxy)₃, C₆.₁₀aryl, C₆.₁₀aryloxy, C₆-ioarylthio, C₆-ioheteroaryl, -(Ci_₈ - perhaloalkyl) , arylCi_₄alkynyl, -d.₆alkynyl, wherein all the alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, arylthio or heteroaryl groups are either substituted or unsubstituted, or two neigboured substituents of A form a -0-Ci-C₄alkyl-0- ring or a -C₄-C₆alkylene- ring together with the carbon atoms to which they are attached and theses rings are optionally substituted by F, CI, Br, -Ci_₄alkoxy;

2. Compounds of formula (I) according to claim 1

R-i is fluorine, chlorine, bromine, cyano, d-C₂alkyl or Ci-C₂haloalkyl;

3. Compounds of formula (I) according to claim 1 or 2 characterized in that

R₂ and R₃ are, independently from each other hydrogen, halogen, d-C₄alkyl, or C₂-C₄alkenyl,

4. Compounds of formula (I) according to claim 1 or 2 characterized in that

W is oxygen, sulphur, nitrogen, Ci-C₆alkylamino,

d-C₆alkylene, C₂- C₆alkenylene, C₃-C₆cycloalkyl, or a direct bond;

or if then A has no meaning W is selected from fluorine, chlorin, bromine, d-₄ alkoxy, Ci.₄ alkylthio;

5. Compounds of formula (I) according to claim 1 characterized in that the

R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, Ci-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups

6. Compounds of formula (I) according to claim 1 characterized in that

n is 0 or 1

7. Compounds of formula (I) according to claim 1 characterized in that

A is selected from

wherein R_a, R_b, R_c, R_d and R_e independently are selected from the group consisting of hydrogen halogen, hydroxy, Ci-C₄alkyl, Ci-C₄haloalkyl, d-C₄alkoxy, Ci-C₄alkylthio, Ci-C₄alkoxy-Ci-C₄alkyl,Ci- C₄haloalkoxy, Ci-C₄alkoximino and Ci-C₄alkylendioxyg roups, or phenyl, pyridyl, thiophene, imidazole or pyrrazol groups

8. A method of controlling or preventing infestation of useful plants by phytopathogenic

microorganisms, wherein a compound of formula (I) as defined in claim 1 or 2 or a composition comprising a compound of formula (I) as defined in claim 1 or 2 as active ingredient, is applied to the plants, to parts thereof or the locus thereof.

9. A composition for controlling and protecting against phytopathogenic microorganisms, comprising a compound of formula (I) as defined in claim 1 or 2 and at least one auxiliary.

10. A method of controlling phytopathogenic diseases on useful plants or plant propagation material thereof, which comprises applying to said plant propagation material a fungicidally effective amount of a plant propagation material protecting composition comprising a compound of formula (I) as defined in claim 1 or 2, together with a suitable carrier therefor.

11. A composition comprising a fungicidally effective amount of a compound of formula (I) as defined in claim 1 or 2, optionally comprising at least one additional active ingredient.